NANOVIRICIDES INC - Neuer Vogelgrippe-Stock - 500 Beiträge pro Seite

[Buddah]

letzte news: http://biz.yahoo.com/bw/051012/125823.html?.v=1

HP:http://www.nanoviricides.com/

sollte man noch aufspringen?

gruss B.

[maxeddi]

Die wird aber nicht in D gehandelt?

[Buddah]

Hallo maxeddi
wird (noch?)nicht in D gehandelt.

gruss b.

[Stock-Fool]

NanoViricides Has Begun Preclinical Studies For Their First Anti-Viral Drug Targeted Against Bird Flu
Monday October 31, 8:00 am ET
Studies Are Being Conducted at the Beth Israel Deaconess Medical Center, a Teaching Hospital of Harvard Medical School


WEST HAVEN, Conn.--(BUSINESS WIRE)--Oct. 31, 2005--NanoViricides, Inc. (Pink Sheets:NNVC - News), today announced that it has commenced preclinical studies for its anti-viral drug FluCide-I(TM). The studies are being conducted at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, under the direction of Dr. Krishna Menon. Dr. Menon, the Company`s Chief Regulatory Officer, explained that nanoviricides are complex materials. "We have started working on the basic safety of the polymer under a maximum tolerated dose protocol in mice. In the second part we will study the ligands that target FluCide-I(TM) to H5N1 and common influenza viruses. Thereafter, we will study the efficacy of FluCide-I(TM) itself against H5N1 and common influenza."
ADVERTISEMENT


Dr. Anil Diwan, President, explained that, "if successful, the relevance of nanoviricides can be compared to the discovery of Penicillin, the very first bactericide. Prior to antibiotics, bacterial infections were treated with patient isolation, chicken soup and Vitamin C. Current anti-viral medicines can at best only partially inhibit the virus from multiplying in the human body. Although we cannot make claims of certainty yet, after we get good results from these studies we will be able to say that we have developed a true virus killer."

The Company is encouraged by the recent statements from high level international officials and health ministers of different countries concerning the urgency of developing effective vaccines and treatments and believes that a rapid regulatory approval of FluCide-I(TM), is possible should these studies be successful.

http://www.nanoviricides.com

[WissenMacht]

danke Budahh und tschüss

[MichiMischtMit]

Verpasst

[Buddah]

Na.Damit konnte man wirklich nicht rechnen:

Bin auch nicht dabei.

gruss B.

[lion_hasser]

MENSCH - verpasst

BUDDHA, das nächste mal 3 monate vorher posten!!

[Buddah]

Thread Erföffnung war von Buddah war am 17.10.05 um 21:09:49
da stand das "ding" noch unter 0,5 Cent....(abgesehen davon,dass ich selbst nicht dabei war)wären doch ein "paar %te" drinnen gewesen...


gruss b.

[lion_hasser]

yep, hast recht - hatte nur den 17. gesehen

[Stock-Fool]

Hi !

Nix verpasst. Der Knall kommt erst noch. In den nächsten 14 Tagen kommen die detaillierten Versuchsergebnisse. Das wird lustig ! Leider wohl kaum noch jemand in dieser Aktie drin. Schade für alle, die diesen Lauf verpassen.

Gruß
Michael

[Stock-Fool]

NanoViricides, Inc. Achieves Broad Success in Initial FluCide-I(TM) Anti-Influenza Studies
Monday March 20, 7:30 am ET
Company Says That Nanoviricides(TM) is Now a Proven Platform To Attack Bird Flu


WEST HAVEN, Conn.--(BUSINESS WIRE)--March 20, 2006--NanoViricides, Inc. (Pink Sheets:NNVC - News), today announced it has received additional results from its FluCide-I(TM) efficacy studies performed at a major US research facility. On the basis of these data, Dr. Krishna Menon, the Company`s Chief Regulatory Officer, said that the drug candidate tested was worthy of filing an Investigational New Drug Application (INDA) with the FDA. "The results were so positive that with an appropriate dosage protocol, it may be possible to save human lives even in bird flu cases using this test nanoviricide itself," suggested Dr. Menon.
ADVERTISEMENT


According to the company`s President, Dr. Anil Diwan, "The study involved our nanomicelle to which a broad-spectrum, anti-influenza test ligand (virus targeting molecule) was attached. This combination of a micelle and ligand is called a nanoviricide(TM). While the objective of the study was to prove that the core technology worked, the results clearly exceeded our expectations. We feel that we have in development the world`s best anti-influenza drug in our hands!"

In a Fast Protocol study, mice were infected with high levels of a human influenza virus. These levels resulted in an untreated survival period of only seven (7) days. A sub-group of these mice were treated with the test nanoviricide 24 hours after infection. The survival time of treated mice was increased significantly at relatively low and safe dosage levels. The safety of the dosage used was confirmed by gross histology as well as microscopic examination of a number of organs and tissues. These results suggest that the dosage can be increased several fold without significant adverse effects and that these higher dosage levels of our nanoviricide(TM) may already be capable of saving human lives in H5N1 bird flu cases.

"We can now say that the nanoviricide is a proven platform," stated Dr. Eugene Seymour, the company`s CEO, "and believe that we can take any enveloped virus and attack it by attaching the right ligand (virus targeting molecule) to the nanomicelle. For instance, we can attack multiple subtypes of influenza by using a broad-spectrum ligand, as we have recently proven, or we can attack a specific virus subtype, such as Highly Pathogenic Avian Influenza (HPAI) and H5N1, with precise ligands that are intended for greater efficacy and specificity." Dr. Seymour also stated that "although the possible extent of any future bird flu pandemic is not at all clear, emergency preparedness purchases by agencies worldwide have been in several billions of dollars. More importantly, the market for a true targeted anti-viral for human influenza is enormous considering the tens of millions of cases diagnosed just in the US and Western Europe alone. Tens of thousands of people die of human influenza year after year."

The truly unique aspect of the technology is that once a drug to attack one virus is created, developing a new drug for another virus involves only changing the targeting molecule, not necessarily the underlying nanomicelle. This novel feature enables us to either respond to a mutating virus or else go after a completely new virus in a relatively short period of time. The Company is currently developing drugs against avian flu (H5N1), emerging highly pathogenic avian influenza threats (HPAI such as H9N2), common influenza, and rabies. The Company plans to develop additional drugs against HIV and Hepatitis C in the near future. "Our goal is to file two INDAs with the FDA within the next 12-18 months," said Dr. Seymour

[spindoctor]

Leider können CoDi-Kunden (wie ich, verdammte schei...) die nur in den USA handelbare Aktie nicht kaufen, da sie ein Pink Sheet ist und die Bank den Kauf verweigert (den Verkauf aber ausführt).

[Stock-Fool]

[posting]20.875.272 von spindoctor am 20.03.06 20:34:26[/posting]Hi Spin !

Haste kein normales Volksbank-Dorfkonto ? Die Könnens.

MfG
Michael

PS: Bin gespannt wie es mit NNVC weitergeht. Zumindest lesen sich die Meldungen bis hierher super.

[MONSIEURCB]

Ein kleiner Hoffnungsschimmer....

NanoViricides Says AviFluCide(TM)-I May be the Leading Drug Against H5N1 Avian Flu
Wednesday June 21, 7:30 am ET

WEST HAVEN, Conn.--(BUSINESS WIRE)--June 21, 2006--NanoViricides, Inc. (Pink Sheets:NNVC - News), today announced that it is extremely proud of the results achieved by the NanoViricides' scientific staff in Hanoi, Vietnam during April and May 2006. The Government of Vietnam was exceptionally cooperative and provided lab facilities, biologics and staff assistance to our team. To our knowledge we are the only company ever to have this opportunity to work within this high level facility of the Ministry of Health. Experiments were continued by the Vietnamese scientists after the NanoViricides scientific team returned to the US. We are now receiving and analyzing the data obtained from these experiments.

The Company believes the results of our bird flu drug, AviFluCide(TM)-I, have established that it is the leading drug against H5N1, based on a preliminary analysis. The Company will coordinate the press release with the Ministry of Health of the Government of Vietnam after the data analysis is completed.

The Company also announced that it has retained the services of the Gencarelli Group of Washington DC for business development purposes. The Gencarelli Group specializes in health and biotechnology business development in both public and private sectors.

At the end of May 2006, Form 144 -Notice of Proposed Sale of Securities, were filed with the SEC by the prior owners of the public shell company (then called edot-com) that became NanoViricides after our merger. This filing listed proposed sales by these shareholders of over 800,000 shares. The company believes that the recent stock price weakness is a result of the sale of these shares.

The company further announced that it has changed auditors as the company has grown quite rapidly and has now engaged the public auditing firm of Holtz Rubenstein Reminick LLP to perform the certified public audit. Holtz Rubenstein Reminick LLP is the "Fastest Growing Accounting Firm in America" (as recognized by both PAR, Sept. 2005, and Accounting Today, Apr. 2006) and one of the Top 25 Accounting Firms in New York (Crain's, Sept. 2005). It is a progressive regional accounting firm, providing a wide variety of accounting, tax and business advisory services to clients throughout the New York metropolitan area.

The audit is expected to be completed in early July. We expect to file with the SEC in order to become a fully reporting company shortly thereafter.

[MONSIEURCB]

na, keiner mehr hier? Sieht doch inzwischen ganz gut aus....abwarten und aussitzen, würde ich sagen!

[MONSIEURCB]

NanoViricides, Inc. Addresses Shareholders on GSK Bird Flu Vaccine
Monday July 31, 7:30 am ET
NanoViricides, Inc., expects billion dollar plus annual market for its influenza drugs

WEST HAVEN, Conn.--(BUSINESS WIRE)--July 31, 2006--Anil Diwan, PhD, NanoViricides' (Pink Sheets: NNVC - News) President, today commented that, "The GSK vaccine has shown significantly better efficacy than the previous vaccines. The GSK vaccine showed an 80% protection in treated individuals. This is still far less than the 95% or better usual clinical protection level of annual influenza vaccines. Using the 80% protection rate, approximately 50% of the population may be expected to show H5N1 bird flu pathology even if a vaccine campaign with the GSK vaccine covered 100% of the world population. The high rates of emergence of resistant viral mutants with existing and developing neuraminidase inhibitor therapies such as Tamiflu(TM), Relenza(TM), or Peramivir(TM), make these therapies unsuitable for widespread strategic use in pandemic containment. In contrast, pre-clinical studies lead us to believe that most of such patients would be curable with our experimental anti-influenza nanoviricides drugs; AviFluCide(TM)-I and FluCide(TM)-I."

The Company's CEO, Eugene Seymour, MD, MPH stated, "It is estimated that over 50 million people in the US and Western Europe become clinically ill with human influenza year after year, despite a strong and effective annual vaccine campaign. Approximately 60,000 deaths occur from common influenza annually within the US and Europe alone. We estimate a multi-billion dollar market for our influenza drugs FluCide(TM) and AviFluCide(TM), drugs which early results can be described as a revolution in medicine."

Other announcements by NanoViricides Inc.:

* Dr. Diwan will be speaking at the Novel Vaccines Conference in August in Boston, MA. The vaccine scientific community has shown a particularly strong interest in the nanoviricides(TM) technology and their ability to rapidly create nanoviricides against emerging threats. There is a deep understanding within the scientific community that vaccines and targeted treatments are the two critically important tools for solving the challenge that a virus presents.
* Additional information will be released to its shareholders over the coming weeks.

[MONSIEURCB]

Heute +18% - weiss jemand, ob NEWS anstehen?

[MONSIEURCB]

News:

NanoViricides, Inc. H5N1 Bird Flu Studies Presented at Novel Vaccines Conference
Tuesday August 29, 7:30 am ET
Three Bird Flu and Influenza Drugs Now in the Pipeline

WEST HAVEN, Conn.--(BUSINESS WIRE)--Aug. 29, 2006--NanoViricides, Inc. (Pink Sheets: NNVC - News) revealed new details of its work in the fight against Bird Flu at a gathering of cutting-edge researchers at the Cambridge Healthcare Institute's conference "Novel Vaccines: Bridging Research, Development and Production" in Boston last week.

"Nanoviricides, Inc. intends to define the next plateau of antiviral therapeutics," Dr. Anil Diwan, the Company's President, told scientists, explaining the Company's work combating H5N1 (avian influenza), the common human flu, as well as the Company's approach against other viral threats such as Hepatitis C and HIV.

"We now have three nanoviricides(TM), all effective against H5N1, entering further detailed studies with the goal of filing INDs," he added, explaining, "the data were fully consistent with our design expectations." Thus, AviFluCide-I(TM) is designed to be specific to H5N1, and FluCide-I(TM) is designed to work against all influenzas, whereas FluCide-HP(TM) is designed to work against the entire highly pathogenic influenza subgroup that poses continuously re-emerging and changing pandemics threats.

Highlighting new information gleaned from H5N1 preclinical studies recently completed in Vietnam, Dr. Diwan showed that many nanoviricide(TM) candidates were effective at as low as 5-nanomolar concentration levels in cell culture experiments. Typically, an early developmental drug that proves effective at concentrations less than 500 nanomolars is considered a strong candidate for FDA approval as an "Investigational New Drug (IND)" applicant.

A nanoviricide(TM) is made by attaching a ligand (targeting molecule) to a core nanomaterial that forms the "viricidal engine" of the assembly. The ligand directs the viricidal engine to find and bind to a specific type of virus. The viricidal engine is designed to be capable of neutralizing most enveloped viruses. Dr. Diwan showed that attaching a ligand to the viricidal engine leads to as much as 50X (5,000%) greater effectiveness compared to the ligand itself. Scientists attending the conference felt that this could have significant implications for developing greatly improved drugs by resurrecting compounds that may have proven marginal or failed earlier.

Bird flu fatalities in 2006 have already topped those in 2005, with Indonesia reporting 60 human cases, and 1 in 5 fatalities. The Centers for Disease Control report that common influenza alone kills 36,000 people in the USA and causes 200,000 people to be hospitalized. "The influenzas represent a multi-billion dollar market if effective drugs can be created even if no epidemics occur," said Eugene Seymour, MD, MPH, the Company CEO.

"We believe NanoViricides, Inc. has the best current drugs in development against bird flu (H5N1), high path influenza, and common influenza," said Dr. Diwan, while acknowledging that "additional studies are needed to further characterize these drugs."

[Stock-Fool]

Antwort auf Beitrag Nr.: 23.667.112 von MONSIEURCB am 29.08.06 14:10:50

Hi Monse !

Schön zu sehen, dass du noch an Bord bist. NNVC kann echt was werden. Eine Meldung von letzter Woche ( NNVC ist nicht erwähnt, hat aber ein Forschungsabkommen mit Vietnam ) :

Vietnam, US sign first official agreement on health

Updated on 7/21/2006 at 18:22

Vietnam and the US on July 20 signed their first official agreement promising continued cooperation on health issues, including emerging diseases, avian and pandemic influenza and HIV/AIDS.

The Agreement on Health and Medical Science was signed in Washington by Vietnamese Minister of Health Tran Thi Trung Chien and U. S. Department of Health and Human Services (HHS) Secretary Mike Leavitt during Minister Chien's visit to the US from July 17-22.

The agreement includes the exchange of information and technical expertise, the development of rapid response plans for Vietnam, personnel training, vaccine production and pharmaceutical product management.

The agreement, a follow up to the letter of intent of cooperation signed by both parties in October 2005 in Hanoi, will take effect as of the signing date and will last for five years.

While in the US, Minister Chien met with the US Under Secretary of State for Global Affairs and the General Director of the National Institute of Health (NIH) in Bethesda, Maryland. She discussed with the World Bank's Director for Human Development and Healthcare about the progress in Vietnam's plan of action on avian influenza and its preparations for responding to avian influenza on humans.

The Minister also worked with the Food and Drug Administration (FDA) and a number of medical organisations.

During the meetings, the Vietnamese Minister informed the US parties of the Vietnamese National Assembly's approval of the Law on HIV/AIDS Prevention, which will lay a firm foundation for the health sector to expand its preventive and cooperative activities.

She spoke highly of the US's timely assistance to Vietnam in the area of healthcare over recent years, particularly in the fight against SARS, avian influenza and HIV/AIDS.

She proposed that the US parties further their assistance to Vietnam in training personnel and upgrading laboratories and equipment.

The US parties praised Vietnam's efforts in combating bird flu, saying that Vietnam is considered a success story and the global health community is studying its actions to be able to duplicate Vietnam's success.

What does the above paragraph imply...it means NNVC will be opening up labs in US and foreign locations. Just my inference. I bet Akin Gumps was involved in developing the MOU/Contract with the Ministry of Health.


----------------------------------------------------

Seitde mziehen die Umsätze an. Ich bin gespannt.

Mit bestem Gruß
Michael

[MONSIEURCB]

Antwort auf Beitrag Nr.: 23.676.159 von Stock-Fool am 29.08.06 22:19:19

Hi, Michael! Danke - gleichfalls..ich hab zwar nur 2500 Stück, aber langfristig könnte das ein ganz schön explosives Teil werden - sie haben eindeutig auf ihrem Gebiet die Nase exklusiv weit vorn. Abwarten, Tee trinken und freuen...Gruß!

[MONSIEURCB]

...und weiter geht's mit guten news:

NanoViricides CEO Releases Details of ''Just In Time'' Manufacturing
Wednesday August 30, 7:30 am ET
Company to Begin Animal Testing of New Drugs This Fall

WEST HAVEN, Conn.--(BUSINESS WIRE)--Aug. 30, 2006--NanoViricides, Inc. (Pink Sheets: NNVC - News) CEO Dr. Eugene Seymour, MD, MPH, says the company is poised to usher in a new era of "just in time manufacturing" of antiviral medications.

In an interview Monday with Wall Street Reporter senior analyst Ian Roberts, Seymour said NanoViricides will be able to rapidly respond to deadly outbreaks." The full interview will be available at wallstreetreporter.com for the next four days.

The relatively simple two-part structure is what makes a nanoviricide(TM) type drug so adept at rapid response.

"The beauty of this whole system is that the nanomicelle(TM) is the same for every viral target. The only thing that changes is the targeting molecule," said Seymour, which could be stockpiled. "Say there's an outbreak of a viral disease for which we have already created and tested a nanoviricide(TM), all we would then do is take the targeting molecule off the shelf, attach it to the nanomicelle, package it and you've got a drug treatment for that disease. That can happen in a matter of days."

Seymour said if NanoViricides' approach is successful it will mark "a completely new way of defining manufacturing in the pharmaceutical industry."

The company has four drugs that will undergo a round of pre-clinical animal testing this fall in Vietnam. They include:

* FluCide(TM)-I - Expected to work against all influenzas.
* AviFluCide(TM) -- Designed specifically to target the H5N1 strain of avian influenza.
* AviFluCide-HP(TM) -- Designed to attack the highly pathogenic influenza subgroup that is continuously re-emerging and changing.
* RabiCide(TM) - Engineered to attack rabies, which remains a major subtropical killer.

Comparing the company's drugs to microscopic cruise missiles, Seymour said all nanoviricide(TM) drugs are composed of two main components. Scientists begin with a 20-nanometer cluster of molecules dubbed a "nanomicelle(TM)", which acts as the vehicle. They then attach the second component, a stripped-down antibody known as a ligand or targeting molecule. This targeting molecule acts as the vehicle's guidance system. The ligand then attaches to a virus, allowing the nanomicelle(TM) to completely encompass the virus envelope and its deadly RNA-replicating core.

"And now that you have the (virus) RNA trapped within this new structure, it is simply digested by the cells of the immune system and turned into its basic chemical components," said Seymour.

NanoViricides is currently focused on expanding its roster of scientists while locating additional research and development facilities, as well as a manufacturing plant.

[MONSIEURCB]

Tja, dann spiel ich eben den Alleinunterhalter weiter...

NanoViricides, Inc. Files SEC Form 10-SB
Wednesday November 15, 8:00 am ET

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NNVC, currently trading on Pink Sheets), -is pleased to report that it has filed Form 10-SB with the Securities and Exchange Commission to become a fully reporting company. The filing can be viewed at the SEC's website: http://www.sec.gov

The Company now awaits comments, if any, from the SEC. Once declared effective by the SEC, the Company will be eligible for listing on the NASD Over the Counter Bulletin Board (OTCBB).

The Company encourages its shareholders to read through the filing which details NanoViricides' accomplishments to date and its strategy for future growth.

The Company also reported that our scientists are continuing to put in extremely long workdays as they prepare for the next stage of the scheduled in-vivo and in-vitro studies.

...daraufhin mailte ich an Leo:

Hallo Leo,
as your name indicates, you have German ancestors (ehrlich = honest). I am a German shareholder of NanoViricides (with quite a lot of shares...) and all I'd HONESTLY like to know is: What are your perspectives for, say 2-3 years? Any ideas about the future of our share price? I know that you're not allowed to share any insider informations, but I could do with a little bright light on the horizon...or a warning in time? Anyway - thanks in
advance!

Und binnen 1 Stunde kam seine Antwort:

Thank you for your straight to the point questions.
We need to better communicate where we will be over the next 2- 3 years. Hopefully that will reflect in the stock price.
We are now working on a strategy for better "communicating" our company to institutions now that we filed the 10SB . It is our belief we are embarking on significant growth (please read the 10SB).
Please write me in another few weeks.
Sincerely
Leo

..hmm...leise köchelts im Hintergrund...

[MONSIEURCB]

NanoViricides, Inc. Begins Rabies Animal Study
Monday January 8, 8:40 am ET
Studies to Be Independently Conducted by Vietnamese Government Scientists

WEST HAVEN, Conn.--(BUSINESS WIRE)--Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc. (Pink Sheets: NNVC - News) announced today that the preliminary animal studies of RabiCide(TM) efficacy are now underway. RabiCide was developed by the company at the behest of Vietnamese health officials. This study is being conducted by the scientists of the National Institute of Hygiene and Epidemiology in Vietnam (NIHE), with the assistance of the Nanoviricides team who supplied the drug.


NanoViricides scientists are in Vietnam for scientific cooperation studies following an invitation by the Vietnamese Ministries of Science and Technology and of Health.

[MONSIEURCB]

+20% bei 1/4 Mio. Volumen...news im Anzug?

[MONSIEURCB]

Übrigens ist dieser thread bei w/ leider nicht mit der Aktie selbst verlinkt - danke für's Nachholen! (..und heute geht's schon wieder +10% hoch...)

[Stock-Fool]

Antwort auf Beitrag Nr.: 27.352.497 von MONSIEURCB am 01.02.07 18:24:16

Hi, Du Alleinunterhalter :-)


Endlich mal wieder Leben in NNVC. Mußte meine Depot leider wegen Nestbau für die Familie mächtig eindampfen und hatte zwischenzeitlich auch echte Bauchschmerzen bei NNVC.

Irgendwie kommt nichts wirklich handfestes von denen. Zwar steigen derzeit Volumen und Kurs, aber ich hoffe echt dass das nicht nur ein Strohfeuer ist.


Mit bestem Gruß

Michael

[MONSIEURCB]

Weiß jemand, wie ich diesen thread mit der Aktie verlinke - oder kann#s jemand erledigen? MERCI!

[MONSIEURCB]

NanoViricides, Inc. Announces Leasing of New R&D Facilities and Corporate Headquarters
Wednesday March 7, 12:53 pm ET

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc, (Pink Sheets: NNVC - News)

Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc. (Pink Sheets: NNVC - News) announced today that the Company has leased 5,000 square feet of an R&D facility originally built for the Bayer Pharmaceutical Corporation in Woodbridge, CT. "This modern space", said Dr. Seymour, "will enable the Company to expand its research activities towards development of new drug candidates and support NanoViricides' anticipated growth".

[MONSIEURCB]

NEWS:

NASD Member Firm Files Form 15c2-11 for NanoViricides To List On OTCBB
Monday March 26, 8:02 am ET

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides', Inc. (Pink Sheets:NNVC - News)

NanoViricides, Inc. is taking steps to move to the OTC Bulletin Board quotation system from the Pink Sheets. The Company is pleased to report that an NASD member firm has filed a Form 15c2-11 with the National Association of Securities Dealers, Inc. for the purposes of obtaining an OTC Bulletin Board listing for the Company's common stock. The OTCBB provides real-time quotes, prices and volume information in over-the-counter (OTC) equity securities. Clearance of the application with NASD to commence quotations of Nanoviricides' common stock on the OTCBB is subject to review and approval by the NASD. If approved, the Company believes it will provide greater visibility for NNVC stock and improved access and information flow for present stockholders and potential investors.

NanoViricides' CEO Eugene Seymour, MD, MPH, stated, "We are excited about this milestone in the development of NanoViricides. We see this as just the first step in our listing strategy. We are working on all fronts to advance the Company as we are now moving into our new R&D facility; working to create collaborative agreements with government agencies; and presenting at conferences to advise scientists and world health experts of our accomplishments. On March 15th, I addressed the 4th International Bird Flu Summit in Washington, DC, and discussed recent findings of our continuing R&D work on AviFluCide-I(TM) and further discussed its intended use, if approved, in treating acute avian influenza infections involving the most virulent strains of the virus such as the H5N1 strains."

An additional discussion of the conference can be found at our website http://nanoviricides.com/fromtheceo.html

The company has filed with the SEC to become a fully reporting company. Filings are available at www.sec.gov

About NanoViricides - http://www.nanoviricides.com

[MONSIEURCB]

NanoViricides' Filing Declared Effective
Wednesday March 28, 7:30 am ET

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc., (Pink Sheets: NNVC - News)

NanoViricides, Inc. announced today that the Company's Form 10-SB, filed originally on November 14, 2006, has been declared effective by the Securities and Exchange Commission ("SEC"). NanoViricides now is subject to reporting and disclosure obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act") including the obligation to file with the SEC periodic reports, such as Annual Reports on Form 10-K (a detailed annual report of the Company's operations), Quarterly Reports on Form 10-Q (a quarterly report of operations) and Current Reports on Form 8-K (a report of significant reportable events).


The effectiveness of its Form 10-SB makes the Company eligible to have its common stock quoted on the NASD Over-The-Counter Bulletin Board upon approval of a recently-submitted application as provided under Exchange Act Rule 15c2-11. NanoViricides cannot predict when its shares of common stock will begin trading on the OTC Bulletin Board but believes it now meets all requirements for doing so.

[Stock-Fool]

Hi Monse,


Neuigkeiten von der Homepage :



FROM THE CEO


To those interested in NanoMedicine:
Welcome to the first in a series of my stream of consciousness musings on the state of viral infectious diseases in the world today and the various attempts at treatment. Since we are now reporting company, there are significant SEC and Sarbanes-Oxley constraints on what I can say. For that reason, there will be no significant insights as to what we're doing or where we're going. At our annual shareholders meeting (to be scheduled) I intend to present much more information since that will also be webcast. All stockholders are invited and thus it will be considered a public forum. I also plan to expand this to a videocast in the near future.
My goal for today is to report on the various presentations given at the 4th International Bird Flu conference held in Washington, DC. I presented there on March 15th. I'd also like to talk about NanoMedicine in general with some thoughts about the future of that field.

Although this message will focus on the Bird Flu conference, I want to remind everyone that, as reported, the avian flu virus is merely one of the viruses we're interested in at the present time. Others include Human Influenza Virus, Rabies, Dengue fever (50 million cases world-wide in the past 5 years), Herpes Simplex, Hepatitis C and HIV. There are others that are of interest to the US government because of their concern about bioterrorism. Drugs for those viruses will be built on demand for the government, but they have little or no commercial applications. Currently one of particular interest is the virus that causes Rift Valley Fever which has been causing outbreaks in the Rift Valley of Kenya.

Another area of particular interest to me are viruses that cause various cancers. The first to discover this fact was Dr. Francis Peyton Rous in 1910. I had an opportunity to meet him in 1960, on the 50th anniversary of his momentous discovery. For the company, this area of research could be considered a very low priority endeavor. I do have a sneaking suspicion that more and more cancers will be found to have a viral etiology. Much like peptic ulcers that were found to have H. pylori (a bacteria) as the causative agent. For an interesting look at NanoMedicine and cancer, the National Cancer Institute nanotechnology section is a wonderful resource: Nanotechnology in Cancer. The work they're funding is absolutely in parallel to what we're doing, only their work is directed at cancer cells.

Now for some interesting history about discovery and the sheer determinism necessary to fully elucidate initial observations.

In 1928, a physician-bacteriologist named Alexander Fleming, working at St. Mary's Hospital in London returned from a long vacation to find his bacterial culture plates "contaminated" by what appeared to be a fungus. Thinking his experiments were ruined, he threw the plates into a liquid antiseptic to first sterilize and then discard them. When a visitor to the lab asked for a tour, he pulled out the only non-submerged plates to complain about his ruined experiment. Upon closer examination, he found a clear zone around the dead bacterial colonies. Then he had a "Eureka" moment that led him on a 12 year quest to determine the nature of the toxin from the fungus and the means of isolating it it.

I mention this only because Dr. Diwan, the inventor of our technology spent the same amount of time before he felt that the technology of building the nanomicelle and attaching the ligand and encapsulated drugs was ready for "prime time." He supported himself by writing software and receiving grants. Another bit of historical information is the contribution of Nobel Prize winner and the inventor of Quantum Electrodynamics, Richard Feynman. He gave a lecture at Cal Tech in December 1959 entitled "There's plenty of room at the bottom" which essentially defined the field of nanotechnology. It took many years for the tools to be developed to exploit his theoretical musings. In chemistry, the field of nanotechnology was advanced by Dr. Richard Smalley, Nobelist at Rice University where Dr. Diwan received his PhD.

Back to the conference: This time, there was great emphasis on preparedness and many of the presenters discussed various measures that were being put in place to have the ability to track all suspected cases. Some described simulations that were done in various countries regarding the response to the first human cases. Others spoke about "surge capacity"; which is the ability of hospitals and emergency rooms in the US to handle a large patient influx. Now there's a joke! I invite anyone to go to a large urban hospital on a Saturday night and tell me if there is any capacity remaining. In Los Angeles, many of the large hospitals stop accepting patients early on Saturday night. So much for "surge capacity" which lies at the core of the emergency response! Look at Toronto in 2003 and tell me if there was any extra capacity. Especially with 45% of those infected being health care workers. Seventy-five thousand deaths are projected in the first month of a pandemic in Los Angeles. Total chaos and anarchy will result. It's like the battle simulations done by the Army. Everything works so well. Fire the first shot and it all goes to hell!

In Toronto nothing worked against the virus. Ribivarin, which is a component of a Hepatitis C treatment, was given out of desperation and later was thought to have made the patients worse.

There was a general consensus on when avian flu would become pandemic in nature. It was thought to be 2 to 3 years out. Either the virus has to further mutate on its own or it has to swap genes with a highly communicable version of the human flu virus. Remember that every bird infected with the low pathogenicity strain of the virus is in itself a living laboratory and the virus is busy mutating. I was asked that question and related my own experience over the years with different influenza outbreaks. My father who was born in 1903 and died in 2000 told me what happened in 1918. He remembered clearly the chaos in New York City associated with the outbreak. During my training, I also had an opportunity to speak with a physician at Bellevue Hospital in New York City who was a young intern in 1918. What he described to me was no different than what was reported by the Vietnamese, Indonesians and Turkish doctors at the conference about the level of severe disease seen in these patients and how frustrating it was to care for them. Then in 1957, my closest friend went off to camp where he got the flu during the 1957 outbreak and died in 24 hours... literally drowning in his own secretions. Then in 1968, as a young military physician, I cared for many very ill soldiers. Quite scary!!

In Indonesia, out of pure desperation (patients were seen in the hospital on the average of eight days after onset of symptoms), people were administered TamiFlu. No one seemed to feel it impacted the course of the disease. That paralleled my own clinical experience where no one seemed to garner any benefit from TamiFlu with human influenza. I must admit that prior to my trip to Vietnam last year, I did spend $160 for 20 capsules (one course of treatment for my wife and myself) that have now expired and will be tossed.

There was also a discussion about vaccines, none of which are yet approved. The Sanofi vaccine was a tremendous disappointment because less than 45% of the volunteers who received the vaccine developed an antibody response to it. And that was with a higher dose than originally anticipated! My personal feeling is that there are four factors that mitigate against widespread use of any approved vaccine. The first is that of human nature... the hesitancy to take a vaccine against a threat that is only theoretical. Secondly is the questionable effectiveness of the vaccine since the endpoint for approval is merely the presence of antibodies. Thirdly, what will be the cost? Will insurance pay for it? An article in Saturday's New York Times addresses that general question and finds that many physicians are neither stocking nor administering certain vaccines because of the failure of the insurance companies to reimburse for them! The fourth reason will be the reluctance of many to be stampeded into taking a vaccine that hasn't been extensively tested over time. This was found during the national campaign to vaccinate everyone against swine flu in 1976. What a disaster! One person died from the flu and 250 died from the effects of the vaccination. I refused to administer it though I took care of patients who had taken it. One was a pediatrician who became quadriplegic afterwards. Another was a man who was paralyzed from the waist down and another was blinded! It was purely a political play.

I spoke about the role we predicted for AviFluCide-I, when and if approved, for the immediate treatment of avian influenza infections. The people from Roche spoke about TamiFlu and its role. They acknowledged that it wouldn't be effective unless it was administered early in the course of the disease and in large doses, which might turn out to be toxic!

So where does this leave us? We are working as fast as possible to continue our AviFluCide-I testing program, first on mice, then ferrets, and depending on FDA directives, primates. We are assuming that our work will fall under the "two animal" rule. We will get that determination when we have our pre-IND meeting with the FDA.

One final thought... we may not have a problem with H5N1 at all. It may be H9N3 or any one of a number of influenza viruses that attack us in a fully activated mode, ready to spread havoc upon the human race!

For an excellent discussion about influenza viruses, look at Wikipedia influenza.

Next time, some rambles on bioterrorism and viruses.

Sincerely,
Eugene Seymour, MD, MPH
Chief Executive Officer.


Quelle : http://www.nanoviricides.com/fromtheceo.html


Gruß

Michael

PS: Schönes Wochenende !

[MONSIEURCB]

Antwort auf Beitrag Nr.: 28.598.865 von Stock-Fool am 31.03.07 11:07:22

Merci, Michael...irgendwie hege ich ja immer noch die Hoffnung, hier irgendwann mal einen legendären Thousandbagger zu halten - toi, toi, toi!

[MONSIEURCB]

Nanoviricides, Inc., and U.S. Defense Dept. Agency Sign Joint Research and Development Agreement to Fight Dengue Fever
Monday April 9, 7:05 am ET
Dengue Fever Treatment R&D Comes as Disease Surges in Hot-climate Regions

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc., (Pink Sheets:NNVC - News), officials announced today that they have signed a Cooperative Research and Development Agreement, or CRADA, with the Walter Reed Army Institute of Research (http://wrair-www.army.mil/)." target="_blank" rel="nofollow ugc noopener">http://wrair-www.army.mil/). The joint R&D effort will focus on creating new treatments for dengue fever using NanoViricides' virus-killing nanomedicine technology. "This collaboration will leverage Walter Reed's extensive experience in dengue fever research with our unique nanoviricide(TM) technology platform for creating anti-viral medications," said NanoViricides' President Dr. Anil Diwan.

About the Walter Reed Army Institute of Research: http://wrair-www.army.mil/

WRAIR is the largest, most diverse, and oldest laboratory in the US Army Medical Research and Materiel Command. It conducts research on a range of issues relevant to the military, including naturally occurring infectious diseases, combat casualty care, operational health hazards, and medical defense against biological and chemical weapons. WRAIR is the Department of Defense's lead agency for infectious disease research and a crucial source of research support for medical product development.

About NanoViricides: http://www.nanoviricides.com

[Stock-Fool]

Antwort auf Beitrag Nr.: 28.729.234 von MONSIEURCB am 09.04.07 17:49:37

Hi Monse !

wünsche frohe Ostern gehabt zu haben.

Liest sich doch recht gut. Mit den offiziellen im Boot sollte auch recht gut an Forschungsgelder ranzukommen sein.


Gruß

Michael

[Stock-Fool]

Hallo !

Das Dengue-Fieber scheint echt eine Plage zu sein :

----------------------------------------------------------
Dengue-Fieber


Andreas Ploch, Arzt


Dengue-Fieber


Beschreibung

Das Dengue-Fieber ist eine Virusinfektion, die in den Tropen vorkommt und weltweit verbreitet ist. Die Erkrankung zählt zur Gruppe der hämorrhagischen Fieber (Fieber mit Blutungsneigung), ebenso wie das Ebola-Fieber und Lassa-Fieber. Meist verläuft das Dengue-Fieber jedoch ohne das Auftreten von Blutungen.

Dengue-Fieber tritt sporadisch, aber auch als Epidemie auf. Betroffen sind vor allem Südostasien, der indische Subkontinent, der Pazifikraum, die Karibik, das tropische Afrika sowie Mittel- und Südamerika.

Die Weltgesundheitsorganisation WHO schätzt die Zahl der Erkrankungen weltweit auf etwa 50 Millionen pro Jahr - Tendenz steigend. Die Dengue-Infektion zählt zu den häufigsten Todesursachen bei Kleinkindern in den genannten Gebieten. Mehrere hunderttausend Erkrankungen verlaufen in der schweren, hämorrhagischen (blutigen) Form, an der jedes Jahr etwa 20.000 Menschen sterben.

Dengue-Fieber tritt auch in Deutschland immer häufiger auf, es wird durch Reisende eingeschleppt. Im Jahr 2004 seien 121 Fälle von Dengue-Fieber aufgetreten, berichtet das Robert Koch Institut (RKI).


------------------------------------------------------

Das steht zumindest so auf Netdoktor.de !

Gruß

Michael

[Stock-Fool]

Hallo,

interessant zu lesen :

http://www.flupatrol.com/2007/04/11/is-nanotechnology-the-fu…



Gruß

Michael

[Stock-Fool]

Hi,

es gibt Neuigkeiten, die Verbindung zu de nBehörden wird gefestigt :

NanoViricides Becomes a Member Of Alliance for Biosecurity
Monday April 16, 7:01 am ET


WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc, (Pink Sheets: NNVC - News)
NanoViricides, Inc., a nano-biopharmaceutical company specializing in the development of novel therapeutics to treat life-threatening viral infections, announced today that it has joined the Alliance for Biosecurity, an association comprised of a leading non-profit biosecurity organization and 14 other biopharmaceutical companies committed to improving the nation's biosecurity through the development of medical countermeasures to address a range of bioterrorism and natural pandemic threats.



Anita Cicero, Executive Director of the Alliance for Biosecurity, commented, "We are delighted to welcome NanoViricides into the Alliance. The company's work in the cutting-edge field of Nanomedicine, combined with its interest in contributing constructive policy suggestions to bolster national Flexible Defense initiatives, will be a significant asset to the Alliance. NanoViricides shares our organization's goal of rapidly accelerating the research, development, and procurement of medical countermeasures that will be needed to respond to both destabilizing pandemics and bioterrorism attacks. With NanoViricides' help, the Alliance will continue its efforts to maximize the promise of Project BioShield and the new Pandemic and All Hazards Preparedness Act."

"Our Rapid Response technologies fit in well with the Flexible Biodefense initiatives that are part of recent US Government acts," said Anil R. Diwan, Ph.D., President, NanoViricides, Inc.

"NanoViricides is honored to be associated with this prestigious organization whose strong membership, comprised of the principal actors in the BioSecurity field, includes some of the most prestigious pharma and biotechnology companies in the world," added Dr. Eugene Seymour, CEO, NanoViricides, Inc.

In other news, NanoViricides, Inc. announced that it has been informed that the nominating NASD member firm has responded to NASD comments on the form 15c2-11submission for NanoViricides to be listed on the over the counter bulletin board (OTC-BB).



Gruß

Michael

[Stock-Fool]

Hallo,

News:

NanoViricides Management Discusses Dengue Fever R&D
Monday April 23, 7:28 am ET
Global Warming and Heavy Rains Reported to Increase Dengue Incidences


WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc, (Pink Sheets: NNVC - News)
The US National Institutes of Health (NIH) had sent out a public warning that "Global Warming Would Foster Spread of Dengue Fever into Some Temperate Regions", as long ago as March, 1998.

ADVERTISEMENT





Since then Dengue's spread has continued and it is emerging rapidly as one of the most important public health problems in many countries. According to the Centers for Disease Control and Prevention in Atlanta (CDC), dengue fever risk is about 1 illness per 1,000 travelers, and it is the most common cause of fever in returned travelers from the Caribbean, Central America, and South Central Asia. The CDC has also noted "dengue is the most important mosquito-borne viral disease affecting humans... Each year, tens of millions of cases of DF occur and, depending on the year, up to hundreds of thousands of cases of Dengue hemorrhagic fever (DHF)."

The recently reported case fatality rate of 11.5% in an outbreak of DHF in Paraguay in Jan-Apr 2007 is much higher than the previous CDC estimate of 5%, which raises additional concerns.

There is currently no vaccine or cure for dengue, which causes high fever, muscular pain, headaches, vomiting, and in some cases skin rash. With 2.5 billion people at risk out of a total world population of 6.6 billion, the potential sales for an effective dengue treatment can be estimated in the hundreds of millions of dollars.

"Our collaboration with Walter Reed Army Institute of Research (WRAIR) should prove to be the best weapon yet in the fight against this globally important and commercially relevant disease," said Dr. Eugene Seymour, MD, MPH.

On April 9, 2007, the Company announced that they had signed a Cooperative Research and Development Agreement with WRAIR, a principal US Department of Defense agency for infectious diseases research.



Gruß

Michael

[Stock-Fool]

Hi,


anziehendes Volumen, kurzer Shake und jetzt wieder Tageshoch.

Sieht nicht schlecht aus :-)

Dazu die Konferenz in 4 Wochen - ich hoffe mal auf Daten aus den Versuchen dieses Frühjahrs.


Gruß

Michael

[Stock-Fool]

Press Release Source: NanoViricides, Inc.


NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
Monday May 7, 7:30 am ET


WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (Pink Sheets: NNVC - News) presented results of recent animal studies against rabies and BSL3 in vitro studies against a Clade 2 H5N1 (avian influenza) virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Symposium)



The BSL3 studies against Clade 2 H5N1, a Dec. 2006 isolate in Vietnam, showed that the nanoviricide developed against Highly Pathogenic Influenzas, FluCide-HP (TM), was highly effective in suppressing cytopathic effects (CPE), whereas the broad-spectrum nanoviricide against all influenzas, FluCide(TM), was slightly less effective than AviFluCide-HP. These findings were expected. Both of these candidates were significantly more effective than oseltamivir (Tamiflu®) in this blind study performed by the National Institute of Hygiene and Epidemiology (NIHE) scientists in Vietnam.

In addition, the antibody-fragment-based H5N1 specific (Clade 1, Vietnam, 2004-2005 strains) AviFluCide(TM) drug candidate was demonstrated conclusively by Vietnam scientists to significantly suppress CPE against this rgH5N1 strain (Clade 1), confirming previous results.

The Highly Pathogenic H5N1 subtype of influenza continues to rapidly evolve and is now found in two distinct subgroups, Clade 1 and Clade 2. According to CDC scientists, the Vietnam 2004/2005 strains belong to Clade 1, whereas the Indonesia 2006 (2007), Egypt 2006, and Vietnam 2006 (2007) strains are different and form the Clade 2 subgroup. The various Clade 2 strains are antigenically distinct from each other, but closer to each other than to Clade 1 strains.

"Highly Pathogenic Influenza strains of all clades possess the polybasic cleavage site. Thus FluCide-HP, designed against this site, is expected to be effective against all Highly Pathogenic influenza strains. It makes no difference to which type, subtype, or clade, they belong," said Anil R. Diwan, Ph.D., president of NanoViricides, Inc.

"We have shown that our drug candidates are the most effective drugs at present against even the newest subgroup of H5N1 viruses. Other companies continue to work on developing vaccines and drugs against the older Clade 1 H5N1 viruses, while we are working on the newest strains," said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc.

The Company plans to comment shortly on its in vitro/in vivo rabies studies.



Gruß

Michael

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides, Inc. Announces Listing in Standard & Poor's Corporation Records and Market Access Program
Thursday August 2, 7:00 am ET

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB - News; the "Company"), announced today that its corporate information is now available via Standard & Poor's ("S&P") Market Access Program. The Company's corporate description was published in the Daily News Section of S&P's Standard Corporation Records on July 31, 2007.

Standard Corporation Records is a recognized securities manual for the "Blue Sky" Standard Manual Exemption for secondary trading in 38 states. As part of S&P's Market Access Program, the Company's corporate information will be made available through S&P's Advisor Insight website (www.advisorinsight.com). The website provides financial advisors with share price, volume dividends, shares outstanding, company financial position and earnings on thousands of companies.

"Being listed in Standard & Poor's is yet another step in our plan to increase our exposure to the investing community," stated Eugene Seymour, MD, NanoViricide's CEO. "We are very pleased with Standard & Poor's decision to include us in its Corporation Records and initiate coverage of us in its Market Access Program."

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, rabies, dengue fever, HIV, hepatitis C, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors.

Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward looking statements are subject to known and unknown risks, uncertainties and other factors including the availability of adequate financing, the success of the Company's research and development strategy, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Such risks, uncertainties and other factors may cause actual results, performance, or achievements of the Company to be different from those expressed or implied by the Company.


Contact:

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
[e-mail]

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

Dengue Virus Therapeutics Program Accelerated at NanoViricides
Monday August 20, 7:00 am ET
The Worldwide and American Rapid Spread of Dengue Driving Development

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC - News; the "Company"), announced today that its Dengue virus therapeutics program is advancing at an accelerated pace.

Dengue fever is gaining a firmer foothold in southern Texas, putting residents at risk for the most dangerous form of the disease, dengue hemorrhagic fever (DHF), U.S. Centers for Disease Control and Prevention (CDC) says in Morbidity and Mortality Weekly Report on August 10th. Doctors and health officials in parts of south Texas should be on the lookout for dengue fever, a tropical virus that can cause internal bleeding and death, CDC said on Aug 9th (http://www.msnbc.msn.com/id/20203770/).

"The US is at significant risk because the Aedes Aegypti mosquito, which carries the Dengue virus, can easily cross borders, and because dengue virus is becoming endemic in Puerto Rico, Mexico, and Central America," said Dr. Eugene Seymour, MD, MPH, CEO of NanoViricides, Inc.

DHF cases have risen to an alarming 25% of dengue fever cases, with overall dengue cases having increased by more than 600 percent in Mexico since 2001, according to Mexico's Public Health Department, reports Mark Stevenson of Associated Press (http://seattletimes.nwsource.com/html/nationworld/2003645837… .html). Also, the Puerto Rican Health Department has recently reported that Dengue has reached epidemic proportions there. The situation is even more acute in Asia with over 33,000 cases of Dengue reported in Vietnam. In addition, Singapore and India are among countries reporting recent outbreaks of Dengue. Globally, there are an estimated 50 to 100 million cases of dengue fever (DF) and several hundred thousand cases of dengue hemorrhagic fever (DHF) per year, according to CDC.

"Therapeutics against Dengue are gaining increased importance because the risk of developing the fatal form, DHF, has been increasing rapidly worldwide, as a significant portion of the world population has had an initial infection with the Dengue virus," said Dr. Anil R. Diwan, President, NanoViricides, Inc. DHF develops primarily in persons reinfected with one of the three remaining dengue viral subtypes, after a previous dengue infection.

NanoViricides, Inc. is preparing to ship dengue-specific as well as broad-spectrum nanoviricides for preclinical testing to Walter Reed Army Institute of Research (WRAIR) within the next several weeks pursuant to a Cooperative Research and Development Agreement (CRADA) signed earlier this year. The dengue-specific ligands are derived from work done by WRAIR scientists.

The new spending authority Defense authorization bill now making its way through Congress designates $5 million for NanoViricides, Inc.'s drug development against Dengue fever, according to a recent announcement by the Washington office of Senator Joseph Lieberman.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

Novel Influenza and Bird Flu Therapeutics Moving Rapidly at NanoViricides, Inc.
Tuesday September 4, 7:00 am ET
Seasonal Influenza and Feared Epidemics Markets Are Large

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC - News; the "Company"), said it is moving rapidly to fill the void in therapeutics against both seasonal influenzas and high path influenzas (H5N1, H7Nx).

Influenza experts claimed that the death toll from seasonal flu is almost as high as if there were an epidemic in Ireland, reported the Irish Examiner (http://www.irishexaminer.com/irishexaminer/pages/story.aspx-… ireland-qqqm=ireland-qqqa=ireland-qqqid=41558-qqqx=1.asp).

"FluCide (TM)-I" is currently the best drug in development against seasonal influenza. Its novel class of action, and the extremely high efficacy levels seen (greater than 800% that of oseltamivir in animal models) have put it at the lead position in the industry," said Anil R. Diwan, Ph.D., President, NanoViricides, Inc., adding, "Further studies are in progress towards the goal of filing an IND (Investigational New Drug) application with the FDA. We are strategizing to enable the shortest possible timeframes in this long process." Oseltamivir is the active ingredient in Tamiflu® (Roche).

Bird flu (H5N1) has now been confirmed by scientists to pass from humans to humans, taking it a step further along to becoming a major epidemic threat, reported Sydney Morning Herald (http://www.smh.com.au/news/world/persontoperson-bird-flu-con… /2007/08/30/1188067276777.html).

"AviFluCide(TM)-I against H5N1, and FluCide-HP(TM) against all highly pathogenic influenza group, have shown extremely high efficacies against highly infectious influenza H5N1 viruses of both Clade 1 and Clade 2 types, beating neuraminidase inhibitors by a wide margin," said Dr. Diwan, adding, "We are ready to start H5N1 animal studies and are awaiting the availability of the most current H5N1 strains."

"Our High Path, H5N1, and Seasonal Influenza drug developments are going strong and we are working towards the goal of filing appropriate INDs with the FDA with rapidity, given the regulations," said Dr. Seymour, adding further, "The commercial market for influenza drugs is extremely large, possibly several billion dollars per year, and expanding. We believe we will be the leaders in this field upon drug approval."

"It will become possible for the US Government to acquire our influenza drugs after we file an IND, even prior to approval, according to the current laws and regulations," said Dr. Diwan.

Ireland had almost 3,500 seasonal-flu and related deaths last year. The US Centers for Disease Control and Prevention (CDC) estimates that between 30 million and 60 million American become ill with human influenza, with an estimated 35,000 deaths, on a yearly basis.

Dr. David Heymann, World Health Organization (WHO) assistant director for communicable diseases, said that WHO is aware of at least three cases where human-to-human transmission of the avian influenza virus was suspected. Dr. Ira Longini's team at the Fred Hutchinson Cancer Research Centre in Seattle, Washington, has for the first time proven that the (H5N1) virus spread between a "cluster" of people. "The world really may have dodged a bullet with that one, and the next time we might not be so lucky," said Dr. Longini.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

Nanoviricides Go Beyond Antibodies in Fighting Bird Flu
Monday September 17, 7:00 am ET
Completes Task of Destroying the Virus Particle

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB - News; the "Company"), said it will be presenting new preclinical data at the 5th International Bird Flu Conference in Las Vegas on September 28th.

"Just like antibodies, nanoviricides(TM) have ligands that attach to the virus particle. However, unlike antibodies, nanoviricides complete the task of taking the virus apart. This is clearly visible in our electron microscopy (EM) studies," said Anil R. Diwan, Ph.D., President of the Company.

"We feel that nanoviricides are the next great advance beyond immunotherapeutics, (use of antibodies and gamma-globulins as treatments for diseases)," explained Dr. Eugene Seymour, MD, MPH, adding, "We have already shown that nanoviricides are superior to FDA approved antibodies in a rabies animal model. This has validated our approach as being the next evolutionary therapeutics platform after antibodies."

"Nanoviricides do not suffer from the major problems of antibodies and of vaccines as antiviral strategies," said Dr. Diwan. Antibodies are relatively specific to a particular virus strain or subtype. It is well known that HIV and influenza viruses among many others, quickly escape antibodies. Vaccines depend upon the development of antibodies by the host, and thus, cannot protect efficiently against such changed viruses, as evidenced for influenzas.

FluCide(TM)-I is a broad-spectrum nanoviricide drug candidate based on a well-known ligand to which influenza viruses of all types must bind and cannot escape. Many other viruses and virus families also bind to this ligand and FluCide-I is expected to work against such viruses as well.

FluCide-HP is a broad-spectrum nanoviricide drug candidate based on well known "signature regions" called "polybasic sites" on all HPAI influenzas including H5N1 and H7N3. If the virus mutates in this region to escape FluCide-HP, its pathogenicity will decrease and it will no longer be a dangerous epidemic threat. FluCide-HP has also shown very high efficacy against the unrelated rabies virus, which possesses similar signature regions.

"Our next step will be to perform animal studies against H5N1 to further validate our results," said Dr. Seymour, adding, "There have been delays in the commissioning of the BSL3+ animal facility in Vietnam. We are currently exploring other options that would permit the studies to be done in the US with the latest available H5N1 strain."

EM photographs of nanoviricides dismantling virus particles are on the Company's website (http://www.nanoviricides.com/action_small.html).

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides Presents Latest Results at Pandemic Flu Conference
Monday October 1, 7:00 am ET
Antigenic Drift Will Not Pose a Problem for NanoViricides' Drugs, says Company

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB - News; the "Company"), presented new preclinical data at the 5th International Bird Flu Conference in Las Vegas on September 28th (http://www.new-fields.com/birdflu5/viewAgenda.php?newsid=2#d…

Dr. Eugene Seymour, MD, MPH, CEO of the Company, presented results of animal studies of FluCide(TM)-I and FluCide(TM)-HP. "In our completely lethal mouse model, efficacy of FluCide-I has improved significantly, and even FluCide-HP, which is designed against high path influenzas, showed very strong efficacy against H1N1, which was the cause of 1918 Spanish Flu pandemic. The improved FluCide-I is now 16X (1,600%) better than oseltamivir (active ingredient of TamiFlu®), and FluCide-HP is 8X (800%) better than oseltamivir, based on dose-response comparisons." Further, in vitro studies have demonstrated that FluCide-HP is significantly superior to FluCide-I against H5N1, as expected.

In addition to discussing the latest research data, Dr. Seymour compared the various treatment options currently available to the practitioner working on the front lines. "Speakers from Vietnam, Indonesia and Turkey made it clear," said Seymour, that "at the present time, no good treatment options exist. These speakers complained that patients sought medical care too late for Tamiflu® - the drug currently recommended by WHO - to be effective. They also pointed out that resistance to Tamiflu develops quickly. Vaccines may be ineffective in the field due to the antigenic drift caused by the observed rapid mutation rate of the influenza virus, according to these physicians. They fear that antibodies alone also will be ineffective as drugs in the field due to the antigenic drift."

"Mutations and antigenic drift should not allow influenza viruses, even H5N1, to escape FluCide-I," said Dr. Seymour. "Similarly, FluCide-HP attacks the invariant features of the signature region that causes high pathogenicity in avian influenza viruses such as H5N1 and H7N3. If a high path virus learns to evade FluCide-HP, it would have lost this signature, and would therefore no longer be highly pathogenic. Thus it would pose only a minimal threat as a pandemic agent," he added.

"We are now working on the necessary paperwork with an agency to begin animal studies against the highly pathogenic H5N1 virus," he reported.

The Company is also working on nanoviricides against Dengue viruses with the Walter Reed Army Institute of Research. Dengue virus is currently causing the worst outbreak in several years in Latin Americas, and has already crossed the border into the USA (http://apnews.myway.com/article/20070930/D8RVGI7O0.html).

[MONSIEURCB]

Der letzte mann an Bord (?) vermeldet:

Press Release Source: NanoViricides, Inc.

NanoViricides, Inc. Presents at the Global Pharma R&D Summit
Tuesday October 23, 7:00 am ET
Nanoviricides Represent Dawn of a New Era in Antiviral Therapy, Says Company

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), presented additional preclinical data at the 4th Annual Global Pharma R&D Summit in Boston on October 22nd (http://www.globalpharmasummit.com/programme.asp).

Dr. Anil R. Diwan, Company President, presented the current results of nanoviricides drug development work against multiple viruses. Significant reduction in lung viral load in influenza H1N1 animal study was described among the new datasets. The one log viral load reduction was especially significant because the treatment was given as a tail vein injection, said Dr. Diwan. The reduction in viral load was corroborated with additional biological tests as well. He also presented the data which indicate that FluCide™-I and FluCide-HP™ may be as much as 10 times (1,000%) to 16 times (1,600%) superior to current treatment standard, oseltamivir (active ingredient of Tamiflu®, Roche) against common influenza, and even better against bird flu (H5N1).

“The era of classical antiviral therapies is coming to an end, with the introduction of highly efficacious nanoviricide drug candidates,” he declared. “Influenza virus cannot escape FluCide-I through mutations, reassortments or recombinations, because of the particular ligand we have chosen, based on sialic acid,” he reiterated in front of the scientific audience in response to a question.

The Global Pharma R&D Summit brings together decision makers from a number of big and mid-size pharmaceutical companies, as well as new technology companies, and features invited presentations.

[Stock-Fool]

Antwort auf Beitrag Nr.: 32.121.342 von MONSIEURCB am 23.10.07 15:50:38

Hi monse !


bist nicht der letzte.

Danke für das posten der news hier. Ich bin gespannt wann mal endlich etwas handfestes von NNVC kommt. Phantasie ist zumindest noch da.


Gruß

S-F

[MONSIEURCB]

Es WIRD immer handfester....

Press Release Source: NanoViricides, Inc.

USAMRIID to Study NanoViricides Against Ebola
Monday October 29, 10:41 am ET
Material Transfer Agreement Signed

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that they have executed a Material Transfer Agreement (MTA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). This joint R&D effort will enable USAMRIID scientists to test the efficacy of several NanoViricides, Inc. anti-viral nanomedicines against deadly hemorrhagic fever viruses at the Ft. Detrick, Maryland BSL4 facilities.

Ebola virus, a highly pathogenic and usually fatal virus found in Africa, will be the initial focus of this joint effort. Animal studies as well as in vitro testing are planned.

“This collaboration is designed to test the efficacy of the nanoviricide approach against this pathogen,” said NanoViricides, Inc. President Dr. Anil Diwan. It is hoped that success against the deadly Ebola virus will lead to further success against other virulent pathogens such as hanta viruses, Marburg virus, Junin virus, Machupo virus, and Rift Valley fever virus. There are currently no FDA-approved treatment options for these diseases.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute’s mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The Institute is working to develop therapeutics for a number of agents, such as Ebola virus, plague, several toxins, and orthopoxviruses.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

[Stock-Fool]

Antwort auf Beitrag Nr.: 32.190.563 von MONSIEURCB am 29.10.07 16:01:51

Hi !


na also, man muß bloß mal fordern

Die offensichtlich immer engere Kooperation mit den Behörden gefällt mir gut.


Gruß

S-F

[MONSIEURCB]

Diew Hoffnung stirbt zuletzt...

Press Release Source: NanoViricides, Inc.

NanoViricides Drug Effectiveness Confirmed against Rabies and Influenzas
Monday November 12, 7:00 am ET
Survival Superior to Standard Antibody Treatment In Rabies-infected Animals

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) said that in a confirmatory study, their nanoviricide™ drug candidates exhibited a consistent 20% to 30% survival in the test animals. In contrast, a commercial anti-rabies antibody produced 0% or no survival, as in the previous study. These results clearly demonstrate the superiority of the multi-valent targeting nanoviricides technology over antibody therapy. Scientists at the National Institute of Hygiene and Epidemiology in Hanoi, Vietnam performed the studies.

ADVERTISEMENT
“Scientific data of this type provides further evidence of the effectiveness of these novel nanomedicines,” said Dr. Eugene Seymour, the Company's CEO. Consistent and reproducible repeat results have also been reported against common influenza (H1N1) using different production batches in animal studies previously performed by the Company.

“The fact that these repeat rabies studies were done in a premier independent government laboratory is extremely important to us,” said CEO Eugene Seymour, MD, adding, “this assures that no inherent bias influenced the outcome. This is of particular importance with any new technology on the cutting-edge of medical treatments. Our confirmatory strategy will be the same with the Ebola and Dengue work that is proceeding in two US government research laboratories.”

An estimated 10 million people receive post-exposure treatments each year after being exposed to rabies-suspect animals. About 30,000 people in the United States receive both pre-and post exposure prophylaxis every year, at a cost of over $1000 per treatment course. The annual number of deaths worldwide caused by rabies is estimated to be 55,000, mostly in rural areas of Africa and Asia, according to a recent World Health Organization report.

Rabies, a uniformly fatal disease found primarily in Africa and Southeast Asia, had never before been successfully treated with drugs.

There are currently no FDA-approved treatment options for rabies once symptoms develop. In addition, the Company believes that significantly increased survival rate of these lethally infected animals is possible in the dose-ranging studies to follow.

[MONSIEURCB]

Form 10QSB for NANOVIRICIDES, INC.

19-Nov-2007

Quarterly Report


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion and analysis should be read in conjunction with our unaudited financial statements and related notes included in this report. This report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The statements contained in this report that are not historic in nature, particularly those that utilize terminology such as "may," "will," "should," "expects," "anticipates," "estimates," "believes," or "plans" or comparable terminology are forward-looking statements based on current expectations and assumptions.

Various risks and uncertainties could cause actual results to differ materially from those expressed in forward-looking statements. All forward-looking statements in this document are based on information currently available to us as of the date of this report, and we assume no obligation to update any forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

OUR CORPORATE HISTORY

NanoViricides, Inc. was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc. and was organized for the purpose of conducting internet retail sales. On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling the Company as a Nevada corporation, Edot-com.com (Nevada). On April 15, 2005, the Company and Edot-com.com (Nevada) were merged and Edot-com.com, Inc., a Nevada corporation, became the surviving entity.

On June 1, 2005, the Company acquired NanoViricides, Inc., a privately owned Florida corporation ("NVI"), pursuant to an Agreement and Plan of Share Exchange (the "Exchange"). NVI was incorporated under the laws of the State of Florida on May 12, 2005 and its sole asset was comprised of a licensing agreement with TheraCour Pharma, Inc. (an approximately 31% shareholder of the Company) for rights to develop and commercialize novel and specifically targeted drugs based on TheraCour's targeting technologies, against a number of human viral diseases. Upon consummation of the Exchange, the Company adopted the business plan of NVI.

Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 newly issued shares of ECMM common stock, resulting in an aggregate of 100,000,000 shares of ECMM common stock issued and outstanding. As a result of the Exchange, NVI became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI Shareholders on a pro rata basis, on the basis of 4,000 shares of the Company's Common Stock for each share of NVI common stock held by such NVI Shareholder at the time of the Exchange.

On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol on the Pink Sheets to "NNVC", respectively.

For financial accounting purposes, this acquisition was a reverse acquisition of the Company by NanoViricides (NVI), under the purchase method of accounting, and was treated as a recapitalization with NanoViricides as the acquirer. Accordingly, our historical financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NanoViricides. With the acquisition of NanoViricides, we no longer remained an inactive entity and entered the pharmaceuticals business.

The Company is considered a development stage company at this time.

Table of Contents

Management's Plan of Operation

The Company's drug development business model was formed in May 2005 with a license to the patents and intellectual property held by Theracour Pharma, Inc., that enabled creation of drugs engineered specifically to combat viral diseases in humans. This exclusive license from Theracour Pharma serves as a foundation for our intellectual property. The Company was granted a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV), human influenza, avian influenza, Influenza and Asian Bird Flu Virus. TheraCour has granted us the right to include dengue fever among the viruses we are able to treat. However, no written agreement has been entered into with TheraCour and no assurance can be given that a written amendment to the licensing agreement with Theracour will ever be reached or that, if reached, will be on terms favorable to the Company.

To date, we have engaged in organizational activities; sourcing compounds and materials; and experimentation with studies on cell cultures and animals. We have generated funding through the issuances of debt and private placement of common stock. We have not generated any revenues and we do not expect to generate revenues in the near future. We may not be successful in developing our drugs and start selling our products when planned, or that we will become profitable in the future. We have incurred net losses in each fiscal period since inception of our operations.

In December 2005, the Company signed a Memorandum of Understanding with the National Institute of Hygiene and Epidemiology in Hanoi (NIHE), a unit of the Vietnamese Government's Ministry of Health. This Memorandum of Understanding calls for cooperation in the development and testing of certain NanoViricides. The parties agreed that the initial target would be the development of drugs against H5N1 (avian influenza). NIHE thereafter requested that we develop a drug for rabies, a request to which we agreed. The initial phase of this agreement called first for laboratory testing, followed by animal testing of several drug candidates developed by the Company. Preliminary laboratory testing of FluCide™-I, AviFluCide-I™ and AviFluCide-HP™ were successfully performed at the laboratories of the National Institute of Hygiene and Epidemiology in Hanoi (NIHE). The second phase of the project, animal and/or additional cell culture testing of the Influenza H1N1 and H5N1 candidates, as well as that of RabiCide-I™, the company's rabies drug, were completed during the first calendar quarter of 2007. Whereas the rabies and H1N1 experimental data have not been completely analyzed, results of the in vitro H5N1 work in Vietnam were reported in a press release on May 7, 2007. The information was as follows: The BSL3 studies against Clade 2 H5N1, a Dec. 2006 isolate in Vietnam, showed that the nanoviricide developed against Highly Pathogenic Influenzas, FluCide-HP ™, was highly effective in suppressing cytopathic effects (CPE), whereas the broad-spectrum nanoviricide against all influenzas, FluCide™, was slightly less effective than AviFluCide-HP. These findings were expected. Both of these candidates were significantly more effective than oseltamivir (Tamiflu®) in this blind study performed by the National Institute of Hygiene and Epidemiology (NIHE) scientists in Vietnam. In addition, the antibody-fragment-based H5N1 specific (Clade 1, Vietnam, 2004-2005 strains) AviFluCide™ drug candidate was demonstrated conclusively by Vietnam scientists to significantly suppress CPE against this rgH5N1 strain (Clade 1), confirming previous results. The Highly Pathogenic H5N1 subtype of influenza continues to rapidly evolve and is now found in two distinct subgroups, Clade 1 and Clade 2. According to CDC scientists, the Vietnam 2004/2005 strains belong to Clade 1, whereas the Indonesia 2006 (2007), Egypt 2006, and Vietnam 2006 (2007) strains are different and form the Clade 2 subgroup. The various Clade 2 strains are antigenically distinct from each other, but closer to each other than to Clade 1 strains. Highly Pathogenic Influenza strains of all clades possess the polybasic cleavage site. Thus FluCide-HP, designed against this site, is expected to be effective against all Highly Pathogenic influenza strains. It is felt that it makes no difference to which type, subtype, or clade, they belong.

On March 12, 2007 the Company signed an agreement and retained a financial advisor to assist us in our capital raising efforts. We paid a retainer fee at signing of $15,000, and services commenced in April 2007.

On April 4, 2007, the Company signed a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The joint R&D effort will focus on creating new treatments for dengue fever using NanoViricides' virus-killing nanomedicine technology. The Company expects to commence work on this agreement upon completion of necessary formalities required under the agreement.

Table of Contents

Management believes that it has achieved significant milestones in the development of rabies and anti-influenza drugs for human influenza (H1N1) and bird flu (H5N1). Management's beliefs are based on the results of pre-clinical cell culture studies and/or in vivo animal studies using mice.

Liquidity and Capital Resources

Requirement for Additional Capital

Based on our current operating expenses, we currently have sufficient cash reserves to meet all of our anticipated obligations through June 30, 2008. As of September 30, 2007 we have a cash balance of $2,738,534, which can support operations through June 30, 2008. However, we expect we will require in excess of $5,000,000 to execute the first part of our business plan which covers twelve months of operations. Assuming that we are successful in raising additional financing, we anticipate that we will incur the following expenses over the next twelve months:

1 Research and Development costs of $1,500,000: Includes planned costs of $1,200,000 for multiple drug variations and in-vivo and in-vitro studies for FluCide™, AviFluCide™, FluCide HP™, and Rabies planned for year ended June 30, 2008. The Company has allocated the planned costs of $1,200,000 approximately as follows: FluCide™ $400,000, AviFluCide™ $300,000, FluCide HP™ $400,000 , and Rabies $100,000. Depending on the results of these clinical trials, we expect to commence with early stage development of a for HIV for which we have budgeted $300,000.

2 Corporate overhead of $750,000: This amount includes budgeted office salaries, legal, accounting and other costs expected to be incurred by being a public reporting company.

3 Capital costs of $1,250,000: This is the estimated cost for equipment and laboratory improvements. The Company plans to incur these costs after completion of certain animal studies, some of which commenced in the third calendar quarter of 2007.

4 Staffing costs of $1,500,000: This is the estimated cost of hiring additional scientific staff and consulting firms to assist with, material characterization, pharmaco-kinetic, pharmaco-dynamic and toxicology studies, as required for development of necessary data for a future filing of an Investigational New Drug Application (IND) with the United States Food and Drug Administration.

The Company will be unable to proceed with its planned drug development, meet its administrative expense requirements, capital costs, or staffing costs without obtaining additional financing of approximately $2,500,000 to meet its budget. The Company does not have any arrangements at this time for equity or other financings. If we are unable to obtain additional financing, our business plan will be significantly delayed.

The Company has limited experience with pharmaceutical drug development. Thus, our budget estimates are not based on experience, but rather based on advice given by our associates and consultants. As such these budget estimates may not be accurate. In addition, the actual work to be performed is not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget. Such changes may also have an adverse impact on our projected timeline of drug development.

On February 27, 2007 the Company leased an R&D facility to occupy 5,000 square feet of space in Woodbridge, Connecticut, originally built for the Bayer Pharmaceutical Corporation. The term of the occupancy is until January 30, 2009 at a monthly rent of $11,667, plus an additional $500 per month for utilities. The Company believes that an adjacent space may become available and would be suitable for small scale manufacturing. The facility will need to be certified by the FDA in order for the Company to produce experimental materials that can be sent to outside scientists for pharmaco-kinetic, pharmaco-dynamic and toxicology studies. These three sets of studies must be completed prior to the Company filing an Investigational New Drug (IND) Application with the FDA to begin the human safety and efficacy trials (Phase I , II and III).

Table of Contents

We believe that this coming year's work-plan will lead us to obtain certain information about the safety and efficacy of some of the drugs under development in animal models. If our studies are not successful, we will have to develop additional drug candidates and perform further studies. If our studies are successful, then we expect to be able to undertake further studies in animal models to obtain necessary data regarding the pharmaco-kinetic and pharmaco-dynamic profiles of our drug candidates. We believe these data will then enable us to file an Investigational New Drug (IND) application, towards the goal of obtaining FDA approval for testing the drugs in human patients.

Most pharmaceutical companies expect 4 to 10 years of study to be required before a drug candidate reaches the IND stage. We believe that because we are working in the infectious agents area, our studies will have objective response end points, and will be of relatively short durations. Our business plan is based on these assumptions. If we find that we have underestimated the time duration of our studies, or we have to undertake additional studies, due to various reasons within or outside of our control, this will grossly and adversely impact both our timelines and our financing requirements.

Management intends to use capital and debt financing, as required, to fund the Company's operations. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to fund its anticipated obligations for the next twelve months.

The Company is considered to be a development stage company and will continue in the development stage until it generates revenues from the sales of its products or services.

Subsequent Events

On October 15, 2007, the Company signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to create new treatments for Filovirus using the Company's nanomedicine technology. Each party is individually responsible for funding its own respective researchers throughout this agreement, including laboratory facilities, salaries, overhead and indirect costs, etc.

While the licensing agreement between the Company and TheraCour does not provide for the use of the nanomaterials we license from TheraCour for the treatment of the Filovirus, TheraCour has permitted the Company to use the nanomaterials to develop a treatment for Filovirus until such time as the Company and TheraCour can negotiate an amendment to the Licensing Agreement to include the Filovirus among the virus types we are permitted to manufacture, use and offer for sale. While the Company is currently negotiating such an amendment with TheraCour, there can be no assurance that an agreement will be reached, in which case TheraCour may revoke our permissive use of its materials for Filovirus, which may adversely impact our operations and cause the termination of our CRADA with the USAMRIID,

[MONSIEURCB]

Totgeglaubte leben länger....

Press Release Source: NanoViricides, Inc.

NanoViricides is on Course to Develop Bird Flu, Influenza, and Other Drugs
Tuesday January 22, 7:00 am ET
CEO Dr. Seymour Discusses Achievements During 2007

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that they are on course with the development of nanoviricides™ drug candidates against highly pathogenic avian influenzas (HPAI) including H5N1 bird flu, and common influenza. “We are now ready to begin animal studies on H5N1 at a renowned federal agency," said Dr. Eugene Seymour, MD, MPH, CEO of the Company. Earlier, the Company had delayed these studies in search of suitable facilities. The work is expected to begin once the contracts are finalized.


Bird Flu H5N1 continues to spread over ever-widening geographic regions and is a major cause of concern for potential pandemic influenza, according to the WHO. This year so far bird flu has spread into six districts in West Bengal, India, causing 120,000 birds to be culled in just 5 days, and 194,000 people to be screened for bird-flu-like symptoms, reports Times of India on January 21, 2008. A boy died of bird flu in Indonesia, and the H5N1 virus was found as far away as a Ukrainian village of Rivne and also northern part of Iran, reports Voice of America. Various research articles have appeared which make researchers fear the virus could mutate and become significantly transmissible between humans.

There are currently no effective treatments against H5N1, or the class of pandemic threatening viruses called HPAI. “The broad-spectrum FluCide™, and the HPAI-specific FluCide-HP™, are designed using the virus’s host cell-binding features that do not change even when the virus mutates,” says Anil R. Diwan, Ph.D., President of the Company. This feature would potentially make these two drugs the best current treatment options for development, says the Company. Vaccines and Antibodies could lose effectiveness due to mutations. H5N1 resistance to Tamiflu® is well known, and resistance against other existing same-class (neuraminidase inhibitor) drugs such as peramivir and possibly Relenza® could occur due to virus mutations.

Dr. Seymour has posted a summary of achievements of the Company on their website. Click here to download the NanoViricides, Inc. 2007 Calendar Year Summary.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides Appoints Leading Hepatitis C Expert to Advisory Board
Monday February 4, 7:00 am ET
Dr. Howard A. Fields joins the Scientific Advisory Board after retiring from the CDC as Team Leader of the Assay Development and Cell Culture Team within the Division of Viral Hepatitis

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Dr. Howard A. Fields has joined the Scientific Advisory Board (SAB) of NanoViricides, Inc. “We are taking steps to accelerate our Hepatitis C antiviral nanoviricides program,” said Eugene Seymour, MD, MPH, CEO of the Company, adding “We are delighted to have Dr Fields, an internationally renowned authority, join our SAB to guide this program.”

ADVERTISEMENT
“I have been very excited by the nanoviricides technology,” said Dr. Fields about his joining the Company’s SAB, adding, “I believe it represents the next step beyond immunotherapeutics, and has great potential.”

Dr. Fields is a distinguished international expert in Viral Hepatitis. During his thirty-two year career at the CDC, he was the Team Leader of Assay Development and Cell Culture Team within the Division of Viral Hepatitis at the Centers for Disease Control and Prevention (CDC), where he led the research on all hepatitis viruses including Hepatitis C virus, and Hepatitis B virus from 2002 until his recent retirement. Prior to that, he was Chief, Molecular and Immunodiagnostic Section (MIDS), Hepatitis Branch, Division of Viral and Rickettsial Diseases. From 1990 to 1994, he was given the responsibility for the conduct of the WHO Collaborating Centre for Reference and Research on Viral Hepatitis at CDC particularly regarding technology transfer issues.

Dr Fields holds six US and international patents, with additional six patent applications pending. He has more than 150 research publications. Dr. Fields holds a PhD in Microbiology from the University of New Hampshire.

[MONSIEURCB]

Hmmm...klingt gut:

Press Release Source: NanoViricides, Inc.

Nanoviricides Found Highly Effective against Ebola by USAMRIID
Tuesday February 19, 7:00 am ET
Broad-spectrum Nanoviricides Demonstrated to Have Excellent Efficacy in Cell Culture Studies

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the broad-spectrum nanoviricides™ drug candidates were found to be highly effective against the deadly Ebola virus in initial cell culture studies by scientists at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

“The fact that the same drug candidates that were highly effective against common influenza and rabies in animal studies and bird flu (H5N1) in cell culture studies were also found to be highly effective against the deadly Ebola virus clearly indicates that these nanoviricides are truly broad-spectrum,” said Eugene Seymour, MD, MPH, CEO of the Company, about the results.

“We have identified common mechanisms by which these very different types of viruses bind to cells and enter cells. We have designed the nanoviricides to display the same features that these viruses look for on the host cell. Our nanoviricides essentially mimic the host cell. We believe this results in fooling the virus to bind to the nanoviricide and be destroyed,” said Anil R. Diwan, Ph.D., President of the Company, adding, “We now have a phenomenal streak of successes of this biomimetic technology as broad-spectrum antivirals.”

Animal studies to test the efficacy of these nanoviricides drug candidates against Ebola infection will be undertaken shortly, according to USAMRIID scientists.

USAMRIID and NanoViricides entered into a Material Transfer Agreement (MTA) in October, 2007. The resulting joint R&D effort enables USAMRIID scientists to test the efficacy of several NanoViricides, Inc. anti-viral nanomedicines against deadly hemorrhagic fever viruses at the Ft. Detrick, Maryland BSL4 facilities.

It is hoped that success against the deadly Ebola virus will lead to further success against other virulent pathogens such as hanta viruses, Marburg virus, Junin virus, Machupo virus, and Rift Valley fever virus. There are currently no FDA-approved treatment options for these diseases.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute’s mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The Institute is working to develop therapeutics for a number of agents, such as Ebola virus, plague, several toxins, and orthopoxviruses.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

[MONSIEURCB]

Klingt weniger gut...

FORM 10 QSB unter:
http://biz.yahoo.com/e/080219/nnvc.ob10qsb.html

..trotzdem heute starker Anstieg...

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides to Begin HIV Animal Trials
Thursday March 27, 7:00 am ET
Harnessing New Therapeutic Opportunities as Vaccine Trial Failures Mount

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB), announced today that preliminary animal trials of HivCide-I™, the Company’s proposed HIV therapeutic, will begin soon at a BSL-3 facility in Boston, MA. The initial results are expected by the second week of May. These animal studies will be conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of novel therapeutics.

“The need for more therapeutic alternatives to combat HIV is greater than ever, especially after the complete failure of two highly-publicized HIV vaccine trials, the first conducted by VaxGen and the second by Merck.” said Eugene Seymour, MD, MPH, CEO of NanoViricides.

Rethinking Is Urged on a Vaccine for AIDS, experts said at a scientific meeting on Tuesday, reported the New York Times. The AIDS Health Care Foundation called for the suspension of money for H.I.V. vaccine research and reallocating resources into effective H.I.V./AIDS prevention, testing and treatment strategies. But Dr. Fauci, the top federal official responsible for AIDS research, strongly rejected the proposal. “Under no circumstances will we stop AIDS vaccine research,” Dr. Fauci said at the conclusion of the meeting, the report further said. (http://www.nytimes.com/2008/03/26/health/policy/ 26HIV.html?_r=1&ref=health&oref=slogin.)

“Control of viremia is the most important factor in keeping HIV infection from developing into symptomatic AIDS,” said Dr. Howard Fields, VP of Virology at the Company, adding “nanoviricides drugs are designed precisely for controlling viremia by eliminating the circulating virus.”

“This is a proof of principle study and will be expanded further with a larger follow-up study to be performed at a major government research institution later in the year,” added Dr. Anil R. Diwan, President of the Company.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

Anti-HIV NanoViricide Drug Candidate Demonstrates Significant Therapeutic Efficacy in Animal Trials
Monday May 5, 7:00 am ET
Positive Initial Results Pave the Way for Definitive Follow-Up Studies

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB), said that its anti-HIV drug candidates demonstrated significant therapeutic efficacy in the recently completed preliminary animal studies. The studies were performed at a Bio-Safety Level 3 Laboratory (BSL-3) facility in Boston, MA. These mouse model studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics.


“Dr. Menon has indicated to us that the results of the study validate the Company’s HivCide-I as a potential treatment for HIV/AIDS,” said Eugene Seymour, MD, MPH, CEO of NanoViricides, adding, “Over the next several weeks, we expect to release additional study data.” The Company’s scientists are now designing the protocol for a follow up anti-HIV study to be performed at a major United States government research facility.

The Company also said that animal studies for its drug candidates against bird flu (H5N1) are due to be scheduled at a major United States government research facility. The company has previously reported that animal studies against Ebola would be undertaken following the success of in vitro studies. These studies are continuing.

NanoViricides, Inc. is using injectable nanoviricides for its initial HIV studies. Future plans call for the development of a long-acting anti-HIV skin patch. The Company feels that this delivery method will result in markedly improved patient compliance.

[MONSIEURCB]

Schöner news flow, schönes Kurs-Comeback..


Click Here! $7 TRADES!

Press Release Source: NanoViricides, Inc.

NanoViricides Inc. Invited to Present at the Centers for Disease Control and Prevention
Tuesday May 13, 7:00 am ET
Institute-wide talk at CDC to discuss both the potential of broad-spectrum nanoviricides and the impact of specific antiviral agent platform technologies for treatment of viral diseases

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC - News), announced that the President of the Company, Dr. Anil R. Diwan, has been invited to address a special institute-wide meeting of CDC scientists at their facility in Atlanta, Georgia. The topic of the presentation will be the use of the novel nanoviricides technology in the treatment of viral diseases. The presentation is scheduled for Tuesday, May 13, 2008, at noon EST. Dr. Diwan will discuss the broad-spectrum nanoviricides. He will also discuss the ability of creating highly specific and effective nanoviricides against particular viral diseases in a very short time span.


In addition to his presentation, a series of private meetings with individual CDC scientists have been scheduled to address particular needs and applications of nanoviricides against a wide range of different viruses and viral diseases.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides' EKC Eye Drug Demonstrates Significant Therapeutic Efficacy in Initial Animal Trials
Monday May 19, 7:00 am ET
First Treatment Success against a Non-Enveloped Virus

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that it has received positive initial results from the animal trials of its drug candidates for the treatment of epidemic keratoconjunctivitis (EKC), a severe viral infection of the eye. Evidence of significant effectiveness was clinically observed in treated infected eyes.

“We were very pleased with the rapid response to treatment, and we had the opportunity to observe the excellent clinical response ourselves,” said Eugene Seymour, MD, MPH, CEO of the Company. “The clinical results we observed are far superior to any data reported in the literature,” said Anil R. Diwan, PhD, President of the Company.

The EKC study which is designed with a duration of four weeks, is currently in progress at a major medical center. Analysis of biological samples is expected to take several weeks following the completion of the study. The Company plans to make preliminary results available publicly as they are obtained.

There are approximately 5 million cases annually of this disease in the US, Europe and Japan. No adequate treatment exists at present. The infection causes severe pain, blurriness of vision and occasional blindness. While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the Company projects the market for EKC and viral conjunctivitis may be several billion dollars annually.

The Company has now shown that two of its broad-spectrum nanoviricide drug candidates have excellent efficacies against substantially different virus types. We have now shown these nanoviricides to be very effective against certain non-enveloped viruses such as the EKC-causing adenovirus. Previously we have shown them to be highly effective against common influenza, bird flu (H5N1), rabies, and Ebola virus.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides in Discussions with Pharma about EKC Eye Drug Candidate
Wednesday May 28, 7:00 am ET
Non-Disclosure Agreements Signed; Meetings Scheduled, says Company

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that it has signed or has in attorney-review non-disclosure agreements with major pharmaceutical companies to enable further discussions regarding the Company’s nanoviricide drug candidate against Epidemic Kerato-Conjunctivitis (EKC). “We have already scheduled meetings to discuss the results of our recent animal studies against EKC,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “We have significant interest from several large pharma companies in both USA and abroad.”

The Company has previously reported that it has received rapid and significant clinical response using a nanoviricide drug candidate eye-drop treatment in animal eyes. EKC was induced by Adenovirus 5 viral infection in this study. The study is now in its final stages and the biological samples collected will be analyzed over the next several weeks.

“We initiated the EKC project as a result of specific interest from certain pharmaceutical companies,” said Dr. Seymour. “We are very pleased with our initial success, despite the fact that adenovirus is a non-enveloped virus,” said Anil R. Diwan, PhD, President of the Company, adding, “It took us a very short time to develop and field a drug candidate against EKC; just a matter of months. This demonstrates the robustness of our underlying technology. We had strong theoretical basis in designing nanoviricide drug candidates against these non-enveloped adenoviruses.”

EKC is a severe and contagious viral infection of the eye in humans. It may cause impaired vision and may lead to blindness. EKC is primarily caused by adenoviruses, although some other viruses may also be the causative agent in humans. EKC may also be caused in some cases by bacterial infections, which are treatable with antibiotics. There is no treatment currently available for viral EKC.

The Company anticipates that the eye-drop formulation of the broad-spectrum nanoviricide drug candidate which was successful against adenoviral EKC may have significant potential against other viral EKC and the less severe viral conjunctivitis diseases as well. Viral conjunctivitis is highly contagious and occurs primarily in schools and other crowded settings, as well as in immuno-compromised populations. While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for EKC is expected to be of the order of several billion dollars annually.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides Inc. Posts Photos Showing Rapid Response of Animals to Treatment with EKC Eye Drug Candidate
Monday June 9, 7:00 am ET
Results Discussed Last Week at Nanotechnology Conference in Boston

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that it has posted photos on its website which show the rapid response to treatment using the Company’s nanoviricide drug candidate against Epidemic Kerato-Conjunctivitis (EKC) (http://www.nanoviricides.com/action_small_EKC_2008-06-09.htm…

The eyes treated with the best nanoviricide drug candidate showed virtual absence of inflammation and significant decrease in the redness of the conjunctiva, i.e. the area surrounding the cornea. The eyes treated with a negative control eye wash solution show the usual redness and inflammation caused by the disease. Substantial improvement occurred within only 2.5 days after treatment in this preliminary study. Further biological analyses are in progress.

“This may be the very first demonstration of a rapid and clear clinical response against adenoviral EKC,” said Anil R. Diwan, PhD, President of the Company, adding, “The robustness of the nanoviricides technology is also now amply evident. We have demonstrated industry-leading efficacies in our very first experiments against widely varying viral diseases such as common influenza, H5N1 bird flu, rabies, Ebola, and now adenoviral EKC.”

“We plan to evaluate this broad-spectrum eye-drop formulation against other viruses causing inflammation of the eye such as herpes simplex virus (HSV),” said Eugene Seymour, MD, MPH, CEO of the Company.

While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for these classes of eye disease is expected to be of the order of several billion dollars annually.

Dr. Seymour discussed these results and the broad-spectrum nature of nanoviricides drug candidates at the NSTI Nanotech 2008 conference in Boston last week.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides Anti-HIV Lead Drug Candidate Demonstrated Substantial Improvement in Survival Time in Animal Model
Monday June 16, 7:00 am ET
Results Better Than Combination Therapy in Double-Blind Animal Study

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB), (the “Company”) said that its lead anti-HIV drug candidate demonstrated markedly superior survival results in the test animals when compared to those animals given the anti-HIV “combo cocktail” in a double-blind animal study. The three-drug combo “cocktail” used for comparison is one of the most frequently used triple combination therapies in humans.

The Company reported that the best nanoviricide anti-HIV drug candidate improved total hours of survival time by 99% with respect to appropriate controls. In contrast, the combo therapy improved survival hours by only 52%. Furthermore, AZT, the first drug used in humans to treat HIV/AIDS, failed to show any survival improvement, as was expected, in this lethality-based animal model study.

The Company also reported that the average body weight loss, a measure of the degree of illness in the experimental subjects, was only 11.4% after treatment with this nanoviricide drug candidate, as compared to 12.9% in those treated with the combo cocktail, and to 23% average body weight loss seen in the untreated control mice.

“We believe these are dramatic results,” said Eugene Seymour, MD, MPH, CEO of the Company, adding that “if these results can be duplicated in humans, triple combo therapy with its toxic side effects may well be replaced in the near future with a much safer single HivCide-I ™ nanoviricide therapy.”

“Another advantage of the HivCide-I nanoviricide is that the treatment can be combined with other existing drug regimens for substantial added benefits,” said Anil R. Diwan, PhD, President of the Company and inventor of the technology, explaining further that “strong improvements should be possible when a nanoviricide is combined with conventional regimen because nanoviricides are designed to act by a novel and completely different mechanism from existing anti-retroviral drugs.”

“As for vaccines [against HIV], it was difficult to predict when they would be developed, but it could be some 10 years from the present time,” remarked Dr. Anthony S. Fauci, M.D., Director of the National Institute of Allergy and Infectious Diseases, at the United Nations General Assembly High Level HIV/AIDS Meeting held on June 10 (http://www0.un.org/News/briefings/docs/2008/080610_AIDS.doc.… Several high level officials have stressed the need for development of better drugs against HIV. Jean-Francois Delfraissy, Director of France's National Agency for Research on AIDS and Viral Hepatitis, said that research "must continue to develop new therapeutic strategies," in Senegal on May 27, according to xinhuanet (http://www.medicalnewstoday.com/articles/109257.php).

AZT is a well known anti-retroviral nucleoside reverse transcriptase inhibitor (NRTI). The combo cocktail employed as a positive control in this study consisted of AZT, 3TC (another NRTI), and Crixivan® (Merck, a Protease Inhibitor), administered orally. All other drugs were administered as injections. Treatment was started 24 hrs after the mice were infected with high (1200 LD50) levels of mouse-adapted HIV-I virus particles. Treatment was repeated twice more at 48 hr intervals.

The studies were performed at a Bio-Safety Level 3 Laboratory (BSL-3) facility in Boston, MA. These mouse model studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics. The Company plans to report additional results from this study as they become available over the next several weeks. The Company is now designing additional studies with the objective of filing an investigational new drug application (IND) to the FDA in the future.

[Buddah]

wow.der Chart sieht ja super aus:

(bin aber nicht investiert) den Investierten:Glückwunsch!

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

Noted Yale Professor, Thomas Lentz, Joins NanoViricides Scientific Advisory Board
Wednesday June 25, 7:00 am ET
Expert in Virus-Cell Interactions had Proposed Blocking them as a Possible Treatment

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB), (the “Company”) said that noted Yale University School of Medicine research physician, Thomas Lentz, MD, has agreed to join the NanoViricides’ Scientific Advisory Board (SAB).

In accepting the invitation, Dr. Lentz commented by email, “As you know, I was an early proponent of the possibility of treating viral infections by blocking the virus-receptor interaction. While most attempts at putting this into practice have not been successful, I believe the innovative approach employed by NanoViricides has great potential.”

Professor Lentz’s research has laid the early foundations for developing anti-viral therapies by blocking virus-cell receptor interactions. His work on the binding of rabies virus to the nicotinic acetylcholine receptor has helped in the creation of a rabies-specific nanoviricide. In addition, his extensive studies on the classification of viruses and of their cellular receptors into broad groups provided the basis for the broad-spectrum nanoviricides that the Company is developing at present as potent therapeutics against a large number of viruses.

Dr. Lentz, whose current title is Senior Research Scientist and Professor Emeritus of Cell Biology was previously also Associate Dean for Admissions and Financial Aid at the School of Medicine (http://www.cellbiology.yale.edu/cellbio/html/faculty/t_lentz…

“It is needless to say that to have Professor Lentz join our SAB is indeed an honor,” commented Dr. Anil Diwan, President of the Company, adding, “We have already benefited substantially from his extensive research in the virus–cell interactions field. His association with the Company should help us tremendously in our mission of destroying viruses in the body and conquering viral diseases.”

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides' Anti-EKC Drug Candidate to Be Studied in Japan
Monday June 30, 7:00 am ET
Renowned Japanese Corneal Researcher Professor Tsubota to Confirm NanoViricides Ekc-Cide(TM) Animal Study Results

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that an internationally renowned Japanese ophthalmologist and corneal researcher, Kazuo Tsubota, MD, PhD, has agreed to perform confirmatory animal efficacy studies of the nanoviricide anti-EKC drug candidate, EKC–Cide™, against EKC (epidemic kerato-conjunctivitis) in Japan. Dr. Tsubota is currently Professor and Chairman of the Department of Ophthalmology at Keio University School of Medicine in Tokyo, Japan.

“NanoViricides’ study of clinical efficacy of EkcCide, is very significant. Their study conclusively demonstrated clearance of the severe pink eye symptoms,” said Dr. Tsubota, after a discussion with the Company scientists in a meeting in Boston last week. He commented, “EKC and herpes virus infections of the eye are important medical problems in Japan, and Japanese pharmaceutical companies have a strong interest in potential treatments,” He continued by saying, “I am very pleased to have the opportunity to confirm the studies in Japan. This is the first step towards obtaining Japanese regulatory approval.”

EKC is a severe and contagious viral infection of the eye in humans which can lead to severe visual impairment. Viral EKC is primarily caused by adenoviruses, although some other viruses may also be the causative agent in humans. There is no currently available treatment for viral EKC.

The Company has previously reported that EkcCide was shown to cause rapid and clear clinical recovery of infected animal eyes in a study conducted by a renowned US ophthalmologic Institute. The infection in this study was caused by adenovirus 5, supplied by the Centers for Disease Control and Prevention (CDC). Representative photographs are posted on the Company’s website (www.nanoviricides.com).

The Company anticipates that the eye-drop formulation of the broad-spectrum nanoviricide drug candidate which was successful against adenoviral EKC may have significant potential against other viral EKC and the less severe viral conjunctivitis diseases as well. Common viral conjunctivitis is highly contagious and occurs primarily in schools and other crowded settings, as well as in immuno-compromised populations. While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for EKC and other viral causes of conjunctivitis is expected to be in the order of several billion dollars annually.

About Kazuo Tsubota, MD, PhD:

An internationally recognized eye specialist, Professor Tsubota is Chairman of the Department of Ophthalmology at Keio University School of Medicine, his alma mater, where he received his MD in 1980. He was the first Japanese recipient of the American Academy of Ophthalmology Honor Award in 1994. He is Chief Surgeon at the Minamiaoyama Eye Clinic in Tokyo, Japan. He heads a large dry eye research group and also the largest refractive (eye) group in Japan, which has several clinics throughout the country. He is author of more than 350 scientific peer reviewed articles. He is an editor of several specialty books in ophthalmology.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricide's EKC Eye Drug Candidate Stopped Clinical Conjunctivitis Pathology
Monday July 14, 7:14 am ET
Statistical Data Analysis Revealed Excellent Efficacy Using Clinical Scores in Animal Study; Confirmed Photographic Findings

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”) reported today that excellent efficacy of its EKC-Cide™ nanoviricide drug candidate was revealed upon statistical analyses of clinical scores from the first animal study.

The EKC-Cide drug candidate clearly demonstrated prevention of conjunctival injection (redness, dilation and prominence of the conjunctival blood vessels) and blepharitis (crusting, discharge and inflammation of the eyelid margins) using mathematical clinical scores calculations. These data confirmed the excellent clinical response observed earlier in eye photographs. In contrast, the control group which received an inactive drop preparation (“negative control”) displayed statistically significant higher clinical scores consistent with the expected strong progression of infection.

A rapid clinical response to the EKC-Cide treatment was also revealed by these data, confirming earlier photograph observations. Substantial differences in clinical scores, demonstrating clear prevention of serious infection and improvement upon treatment, were observed within three days after treatment. Moreover, while both scored parameters (conjunctivitis and blepharitis) were still significantly elevated even at day 10 in the “negative control” group; in the EKC-Cide treated group both parameters had returned to normal already at day 7, indicating full recovery.

These clinical scores were based on daily observations and recording of the animals by trained observers. Further biological analyses are in progress.

“These results confirm our earlier preliminary photographic evidence,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “We now know that EKC-Cide efficacy is substantially superior to that of other drugs in development against EKC.”

The Company has previously posted photos on its website which demonstrated the rapid response to treatment using the Company’s nanoviricide drug candidate against Epidemic Kerato-Conjunctivitis (EKC) (http://www.nanoviricides.com/action_small_EKC_2008-06-09.htm…

“EKC-Cide may have efficacy against other viral conjunctivitis as well,” said Anil R. Diwan, Ph.D., President of the Company, “It uses a broad-spectrum ligand for finding the virus. Binding sites for this ligand may be present on a large number of viruses.” The Company plans to evaluate this broad-spectrum eye-drop formulation against other viruses that cause eye diseases such as herpes simplex virus (HSV).

The Company has previously reported that it is in talks with certain pharmaceutical companies regarding potential licensing of a nanoviricide against adenoviral EKC.

The two clinical scores employed were for “conjunctival injection” i.e. redness and dilation or prominence of conjunctival blood vessels, and for “blepharitis” i.e. crusting, discharge and inflammation of eyelid margins. Both are classic signs of pathological infection.

While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for these classes of eye disease is expected to be of the order of several billion dollars annually.

EKC is a highly contagious and very severe inflammation of the eyes that results in disabling red eyes, discharge and inflammation of the eyelids with clinical symptoms lasting several weeks. Bacterial conjunctivitis may be treated with antibiotics; however, there is no treatment currently available for viral EKC. Further, viral EKC, in some cases, may result in the formation of hazy spots in the cornea called “sub-epithelial infiltrates” which cause blurriness of vision, a condition that may last up to two years.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides, Inc. Added to the Ludlow Biotech Index
Monday July 21, 11:10 am ET

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) a development stage company that is creating special purpose nanomaterials for the treatment of viral infections, today announced that the company has been added to the Ludlow Biotech Index.

Tom Bustamante, the Managing Partner of Ludlow BioVentures commented, “NanoViricides utilizes creative and unique nanomaterials for targeting and destroying viruses. The company's nanoviricides™ drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. NanoViricides, Inc. is thus creating treatments that need to be given only to patients that contract a viral disease, as opposed to vaccines, which must be given to substantially the entire population to prevent the occurrence of an epidemic. Nanoviricide drugs form a novel class of drugs, that is complementary to other existing viral therapies. This unique approach makes NNVC an interesting play in the field of viral therapy, and should provide for additional depth to our biotechnology stock index.”

The Ludlow Biotech Index is a diverse basket of biotechnology stocks, that includes well established biotech stocks such as Amgen, Biogen-Idec, and Genzyme. This index provides institutional investors a means to track and trade a basket of small cap biotechnology stocks, with reduced risk through diversification. The Ludlow Biotech Index is owned and operated by Ludlow Capital Group, Inc.

For additional information on the Ludlow Biotech Index and its components visit http://www.ludlowcapital.com/indices/biotech/

Disclosure

NanoViricides, Inc. is not a client of Ludlow BioVentures. NanoViricides, Inc. has not paid any compensation to Ludlow for inclusion of NNVC in the Ludlow Biotech Index.

About Ludlow BioVentures:Based in New York City, Ludlow BioVentures is a venture capital and research advisory firm with a specific focus on the biotechnology sector. The goal of the firm is to promote investments into biotech ventures worldwide. Ludlow BioVentures owns and operates the Ludlow Biotech Index, which tracks a wide basket of US traded large and small cap biotechnology stocks. www.ludlowcapital.com/bioventures/

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides Inc. Appoints Renowned Ophthalmologist Dr. Kazuo Tsubota to Scientific Advisory Board
Monday July 28, 7:00 am ET
Significant Interest from Japanese Pharmas in EKC Drug Candidate

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that the internationally renowned Japanese ophthalmologist and corneal researcher, Kazuo Tsubota, MD, PhD, has agreed to join the Company’s Scientific Advisory Board. Dr. Tsubota is currently Professor and Chairman of the Department of Ophthalmology at Keio University School of Medicine in Tokyo, Japan.

“I have already had licensing discussions with Japanese pharmaceutical companies regarding EkcCide™,” said Dr. Tsubota, adding, “There has been significant interest in Japan in the excellent animal study results from the Institute in New York.”

“Dr. Tsubota will be helping us prepare the Company’s nanoviricides drug candidates to enter the regulatory approval process in Japan. Initially, he will focus on viral eye diseases such as EKC and Herpes virus infection, among others,” said Eugene Seymour, MD, MPH, CEO of the Company.

There are a number of different viruses that cause both viral conjunctivitis and keratitis (inflammation of the cornea). Adenovirus is a common cause of the very severe and potentially debilitating EKC. Herpes simplex virus (HSV-1) is another important infection of the eye. HSV-I infection is frequently recurrent and can lead to corneal scarring which may necessitate corneal transplantation.

The Company has previously reported that EkcCide was shown to cause rapid and clear clinical recovery of infected animal eyes in a study conducted by a renowned US ophthalmologic Institute. The infection in this study was caused by adenovirus 5, supplied by the Centers for Disease Control and Prevention (CDC). Representative photographs are posted on the Company’s website (www.nanoviricides.com).

EkcCide is the Company’s nanoviricide™ drug candidate designed against the adenovirus that causes epidemic-kerato-conjunctivitis (EKC). The Company anticipates that the eye-drop formulation of this broad-spectrum nanoviricide drug candidate may have significant potential against other viral causes of EKC, herpes infection of the eye and the less severe viral conjunctivitis diseases as well. Common viral conjunctivitis is highly contagious and occurs primarily in schools and other crowded settings, as well as in immuno-compromised populations. While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for EKC and other viral causes of conjunctivitis is expected to be in the order of several billion dollars annually.

About Kazuo Tsubota, MD, PhD:

An internationally recognized eye specialist, Professor Tsubota is Chairman of the Department of Ophthalmology at Keio University School of Medicine, his alma mater, where he received his MD in 1980. He was the first Japanese recipient of the American Academy of Ophthalmology Honor Award in 1994. He is Chief Surgeon at the Minamiaoyama Eye Clinic in Tokyo, Japan. He heads a large dry eye research group and also the largest refractive (eye) group in Japan, which has several clinics throughout the country. He is author of more than 350 scientific peer reviewed articles. He is editor of several specialty books in ophthalmology and is also a reviewer for many international journals in ophthalmology.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides, Inc. Signs Rabies Agreement with CDC for Expanded Research
Monday August 4, 7:00 am ET
Study to Evaluate Usage Strategy for further Development towards Drug Approval

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB), (the “Company”) said that it has signed a Materials Cooperative Research and Development Agreement (MCRADA) with the United States Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia for rabies treatment study. The study, to be performed in collaboration with the CDC Rabies Program, is scheduled to begin soon.

ADVERTISEMENT
“This study will expand on two successful animal studies of RabiCide™-I performed previously by the government of Vietnam,” said Eugene Seymour, MD, MPH, CEO of the Company, adding that “In those prior studies we achieved a 25% to 30% survival rate in animals that had already developed rabies. We believe this strong survival rate is a historical first achievement for any post-infection rabies treatment.”

“Collaborating with CDC in designing and conducting these studies is an important step forward,” said Anil R. Diwan, PhD, President of the Company, adding, “If the current studies are successful, we anticipate that this will be instrumental in helping our anti-rabies nanoviricide towards drug approval and widespread use across the world.”

The Company has previously reported that Yale Research Professor Thomas Lentz, a leading expert in antiviral therapeutics based on virus-cell binding, has joined the Scientific Advisory Board. Prof. Lentz studied the binding of rabies virus to various cell receptors and has performed pioneering research in this field. The Company believes that it has put together a strong team to tackle rabies.

About the Centers for Disease Control and Prevention (CDC):

The Centers for Disease Control and Prevention is an organization that protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing creditable information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations. As a federal agency, CDC does not promote or endorse specific products or entities. For more information please visit www.cdc.gov.

About Rabies:

Rabies is a uniformly fatal disease (i.e. 100% death rate upon infection), and cannot be cured after infection occurs, except in very rare cases. Rabies is transmitted to humans upon getting bitten by mammals such as bats and canines (dogs, raccoons, foxes, etc.). The World Health Organization estimates that more than 55,000 people die each year from rabies, mostly in Asia, Africa and Latin America. An estimated 10 million people receive prophylactic treatment against rabies due to exposure to potentially rabid animals. Rabies is a viral zoonotic (infectious disease transmitted by animals to humans) neuroinvasive disease that causes acute encephalitis (inflammation of the brain) in mammals. There are only six known survivors of clinical rabies. For more information please visit www.cdc.gov/rabies.

Rabies prophylaxis and treatment market worldwide is estimated to be well in excess of $300 million.

[MONSIEURCB]

Jetzt wird's ECHT interessant: AIDS-Bekämpfung!!!

Press Release Source: NanoViricides, Inc.

NanoViricides, Inc. Reports that HIVCide-I Was Significantly Superior to the Current Anti-HIV Three Drug Cocktail Standard
Monday August 11, 7:00 am ET
The Novel Mechanism of Action of HIVCide-I Defines a New Class of Anti-HIV Drugs

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB), (the “Company”) said that additional biological tests and data analysis have shown that animals treated with its lead anti-HIV drug candidate, HIVCide™-I, demonstrated a substantially greater reduction in viral load -- number of infectious virus particles per milliliter of blood -- when compared to the animals given the anti-HIV “combo cocktail” in a preliminary animal study. An important objective of anti-HIV treatment is to minimize the viral load.

These new data expand on the findings previously reported and are consistent with earlier results. The Company has previously reported that HIVCide-I was substantially superior to the combo therapy in improvement of survival time, as well as in reducing the body weight loss, in this preliminary animal study.

“We now know that HIVCide-I was clearly superior to the triple drug combo cocktail in all parameters we observed,” said Anil R. Diwan, PhD, President of the Company, adding, “The novel mechanism of action of HIVCide-I defines a new class of anti-HIV drugs. This enables that it can be combined with the existing cocktail. In such a combination, a much greater level of effectiveness could be achieved compared to what is possible today.”

”If our preliminary results can be duplicated in humans, it is quite possible that HIVCide-I, either alone or in combination with the current combo cocktail, may provide a ‘functional cure’ for HIV/AIDS,” said Eugene Seymour, MD, MPH, CEO of the Company.

Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID), NIH, recently described “functional cure” as a state short of true HIV cure that allows a patient to live a life practically free of HIV following prolonged treatment, although the infection may still be present in a latent fashion. True cure (complete freedom from HIV) may be much more difficult to achieve than functional cure because the virus hides in immune cells that make up “latent reservoirs” (http://www.cnn.com/2008/HEALTH/conditions/08/05/ fauci.hiv.column/index.html).

The Company is now in discussions with renowned HIV scientists as to the nature of the additional experiments needed to develop the nanoviricide drug candidate for FDA approval.

These Bio-Safety Level 3 studies employing the well known SCID-hu Thy/Liv HIV mouse model were supervised by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc. NNVC

NanoViricides Inc. on Panel at the SALSS 2008 Conference in Stockholm
Monday August 25, 7:00 am ET
EKC, HIV Results, as well as Broad-Spectrum Nanoviricides Capability Presented

WEST HAVEN, CONN.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that Anil R. Diwan, PhD, President of the Company, was a participant in a panel on global pharmaceutical strategies at the Fourth Annual Swedish-American Life Sciences Summit held August 20-22, 2008 in Stockholm, Sweden. Speaking in front of a large pharmaceutical and life sciences finance industry group, he enumerated the accomplishments of the Company. He also presented his thoughts on the Company’s global strategy for supplying nanoviricides treatments for serious viral diseases to both developed and developing countries.

ADVERTISEMENT
Dr. Diwan was invited as a panel member on the panel discussion “Emerging Life Sciences in a Global Context- A New Necessity” held last Friday. After discussing the Company’s accomplishments, he spoke about the successes of the nanoviricides technology. In response to a question, he said that the Company has a strong focus on commercially important disease targets such as Influenza, Bird Flu, viral diseases of the eye, HIV, and Hepatitis C. He added that the Company has developed a unique broad-spectrum antiviral technology that can work well against a large number of different viruses. Using such agents, it will be possible to develop cost-effective treatment strategies against lethal diseases of the developing world such as Rabies, Dengue virus, and many others. Many of these diseases are now being seen more frequently in developed countries also.

The Fourth SALSS featured leaders of Life Sciences industry in both Sweden and the United States. This forum brought together key pharmaceutical executives, entrepreneurs, venture capitalists and financiers, and key scientists from both countries in an invitation-only open-discussion format. (http://www.marketwatch.com/news/story/swedish-american-life -science-summit-stockholm/story.aspx?guid=%7B0D2BC44F-BFBF-4F8A-ACA8 -55E5DCEAFC45%7D&dist=hppr).

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides, Inc. to File Annual Report Shortly; Discusses Status of Current Projects
Monday October 6, 7:00 am ET
Temporary Stock Symbol Change Will Be Reversed

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), commented on the recent and temporary change of its quotation symbol from NNVC.OB to NNVCE.OB. The “E” reflects that the Company has not yet filed its Form 10-KSB, annual report to shareholders. The Company’s symbol will return to NNVC.OB once the Form 10-KSB is filed. The Company anticipates it will file our annual report within the time provided and expects there to be no significant change in its financial statements.

Commenting on this event, Eugene Seymour, MD, MPH, the Company’s Chief Executive Officer, stated “We want to assure our stockholders that nothing about the Company has changed. We remain committed to both our mission and our science and we will rectify this issue within ten days.”

“Following recently disclosed successful financing, we are now busy scheduling the follow-on studies against HIV as well as adenoviral EKC. We have received significant interest from several major pharmaceutical companies, as well as governmental and non-profit institutions for nanoviricides development against these diseases,” he further added.

“We are now gathering significant and valuable input for these studies from important stakeholders interested in furthering development of highly effective drugs against these major diseases,” said Anil R. Diwan, PhD, President of the Company.

The Company further reports that the next stage in the evaluation of anti-rabies nanoviricides is expected to begin soon at the Centers for Disease Control and Prevention in Atlanta, GA, under a previously announced signed Materials Cooperative Research and Development Agreement (M-CRADA). The anti-influenza projects, viz. FluCide™-I against common influenzas, and FluCide-HP™ against all highly pathogenic avian influenzas (bird flu, including H5N1, H7N and H9N), are awaiting certain animal studies protocol approvals. The Company is currently developing additional ligands against the Ebola virus, following successful initial in vitro studies, to overcome the potential problem of soluble surface glycoprotein shed by the virus in animal infection. The Company plans to report on additional projects undertaken as they proceed.

[MONSIEURCB]

Press Release Source: NanoViricides, Inc.

NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics
Monday October 20, 7:00 am ET
Company to File Annual Report Shortly

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it participated in a meeting of international experts on Dengue Therapeutics held by the Special Programme for Research and Training in Tropical Diseases (TDR), of the World Health Organization (WHO), in Geneva, Switzerland on October 2, 2008.

“Viral load reduction was clearly recognized as an important goal in Dengue treatment at this meeting. Nanoviricides are well suited for Dengue treatment because they are specifically designed for viral load reduction. We believe that our novel nanomedicine-based direct antiviral approach will be of great value in combating the Dengue viruses,” said Anil R. Diwan, PhD, President of the Company, who participated in the meeting.

In another note, the Company clarified that the deadline for filing its Annual Report on Form 10-K, within the thirty day grace period allowed, is October 29, 2008. The Company, its counsel, public auditors and internal accountants, are committed to finalizing and filing the report accordingly. The Company expects to file the Annual Report shortly. When the Company files its annual report, the “E” will be removed from the Company’s symbol, changing it back to the normal NNVC. The presence of an “e” (i.e. NNVCE) does not constitute a trading halt or delisting of the company’s stock. It resulted from the original filing date for the annual report being exceeded.

NIAID experts see dengue as an important potential threat to the US public health (http://www.nih.gov/news/pr/jan2008/niaid-08.htm). The mosquito vectors that carry dengue viruses have been found in 36 or more states. Human infections in southern states have also been reported. Worldwide, dengue is among the most important reemerging infectious diseases with an estimated 50 to 100 million annual cases and 22,000 deaths. Dengue has become endemic in many tropical countries. (www.iht.com/articles/2008/05/15/healthscience/13brod.php).

Dengue fever is caused by one of four dengue virus types. Most people when they get the first infection have mild disease. A second infection with a different type of dengue virus can lead to a severe and life-threatening form of dengue disease, called severe dengue or dengue hemorrhagic fever. Thus people who have had a primary infection are primed for a severe form of the disease. Dengue severity is expected to continue to increase worldwide.

There are currently no drug treatments or vaccines against dengue.

[MONSIEURCB]

hmmm...nun ja....


http://finance.yahoo.com/q/is?s=nnvc.ob

[MONSIEURCB]

Vielleicht mach ich einen Riesen-Fehler, für den ich mir in 10 Jahren mal in den Pop beiße, wenn NANO die Welt vor der Vogelgrippe und Aids gerettet hat und die Aktie bei 100€ liegt ... aber ich steig trotzdem aus - vor allem, weil der Wert in DOLLAR bemessen wird - und auf den geb ich keinen Pfifferling mehr. Hugh! Allen Investierten weiterhin viel Glück -- ciao

[Stock-Fool]

NNVC mischt jetzt auch bei der Schweine-Grippe mit:

NanoViricides, Inc. Says Flu-Cide Drug Designed to Destroy All Influenza A Viruses Including Swine and Bird Flu
Already shown to be effective against diverse influenza subtypes such as H1N1 and different clades of H5N1

On Monday April 27, 2009, 7:00 am EDT
Print Related:NanoViricides, Inc.
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it is developing FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.

Related Quotes
Symbol Price Change
NNVC.OB 1.07 +0.27


The Company has previously announced excellent results in both animal studies and cell culture studies against widely different influenza subtypes and strains. If these results are confirmed in further animal and human studies, then FluCide would likely be considered the best ever drug effective against all influenzas. The Company is communicating its capabilities to various agencies involved in the current epidemic response.

The current swine flu outbreak is significant in that the H1N1 virus causing it is novel The US Department of Homeland Security has declared a Swine Flu Emergency yesterday. The WHO has said that the outbreak is an emergency of international concern The pig is known to be a transitional species for influenza viruses. That means re-assortment (i.e. mixing) of genes from bird flu, human flu, and swine flu viruses can take place in pigs. This can lead to more lethal, drug resistant novel strains to emerge from different existing ones.

"Nanoviricides(™) have clear advantages over antibodies and vaccines as antiviral strategies," said Dr. Diwan, President of NanoViricides. Antibodies are relatively specific to a particular virus strain or subtype. It is well known that HIV and influenza viruses among many others, quickly escape antibodies. Vaccines depend upon the development of antibodies by the host, and thus, cannot protect efficiently against those viruses which are continually changing their character, such as the influenza virus. Influenza vaccines in particular have to be developed with the strain that is expected to infect in the next year’s cycle. It is well known that this is not a failure-proof strategy for epidemic-causing strains that are novel.



Gruß

S-F

[Stock-Fool]

NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99%
Press Release
Source: NanoViricides, Inc.

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates. The studies were performed by Thevac in Baton Rouge, LA, in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine under the supervision of Dr. Gus Kousoulas.


Four different nanoviricides showed greater than 10,000-fold (>99.99%) reduction in virus quantity compared to untreated controls in a cell culture assay employing the LSU proprietary green-fluorescent-protein-tagged (GFP) modified HSV-1 McKrae strain.

These nanoviricide drug candidates are designed to act against all herpes simplex virus strains, including HSV-1 and HSV-2. The Company has commissioned additional in vitro studies to confirm the results. Animal studies have also been scheduled.

“We are very excited with this success against HSV-1,” said Eugene Seymour, MD, MPH, CEO of the Company, adding “and expect this to lead to a topical skin cream against herpes cold sores and genital herpes. This opens up another significant commercial opportunity for the Company.”

Herpes simplex virus (HSV) causes “cold sores”, the incidence of which is second only to the common cold (100 million recurrences annually in the US alone). In addition, genital herpes prevalence is 67 million infected individuals in the US alone. HSV also causes keratitis, a disease of the eye (250,000 US cases/year).

Existing therapies include acyclovir and drugs chemically related to it. These drugs, nucleoside analogs, act by inhibiting viral DNA synthesis. However, there is known drug toxicity due to interference with human metabolism. Currently, there is no cure for herpes infection.

Nanoviricides act by a novel and distinctly different mechanism compared to existing drugs. Nanoviricides are designed to mimic the human cell surface to which the virus binds. Our results suggest that a nanoviricide could become a highly sought after drug against HSV.

The market size for herpes simplex virus treatments is in excess of $2 billion annually